Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia (Review)

El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H


www.cochranelibrary.com
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia (Review)

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ABSTRACT

Background
Tardive dyskinesia (TD) is a disabling movement disorder associated with the prolonged use of antipsychotic medication. Several strategies have been examined in the treatment of TD. Currently, however, there is no clear evidence of the effectiveness of these drugs in TD and they have been associated with many side effects. One particular strategy would be to use pharmaceutical agents which are known to influence the catecholaminergic system at various junctures.

Objectives
1. To determine the effects of any of the following drugs for antipsychotic-induced TD in people with schizophrenia or other chronic mental illnesses.
   i. Drugs which influence the noradrenergic system.
   ii. Dopamine receptor agonists.
   iii. Dopamine receptor antagonists.
   iv. Dopamine-depletor drugs.
   v. Drugs that increase the production or release of dopamine.
2. To examine whether any improvement occurred with short periods of intervention (less than 6 weeks) and, if this did occur, whether this effect was maintained at longer periods of follow-up.
3. To examine if there was a differential effect for the various compounds.
4. To examine whether the use of non-antipsychotic catecholaminergic drugs are most effective in those with more recent onset TD (less than five years).

Search methods
We retrieved 712 references from searching the Cochrane Schizophrenia Group Trials Register (July 2015 and April 2017). We also inspected references of all identified studies for further trials and contacted authors of trials for additional information.

Selection criteria
We selected studies if they were randomised controlled trials focusing on people with schizophrenia or other chronic mental illnesses and antipsychotic-induced tardive dyskinesia. We compared the use of catecholaminergic interventions versus placebo, no intervention, or any other intervention for the treatment of antipsychotic-induced tardive dyskinesia.
Data collection and analysis

We independently extracted data from these trials and we estimated risk ratios (RRs) with 95% confidence intervals (CIs). We assumed that people who left the studies early had no improvement.

Main results

There are 10 included trials (N = 261) published between 1973 and 2010; eight are new from the 2015 and 2017 update searches. Forty-eight studies are excluded. Participants were mostly chronically mentally ill inpatients in their 50s, and studies were primarily of short (2 to 6 weeks) duration. The overall risk of bias in these studies was unclear, mainly due to poor reporting of allocation concealment and generation of the sequence. Studies were also not clearly blinded and we are unsure if data are incomplete or selectively reported, or if other biases were operating.

One small, three-arm trial found that both alpha-methylldopa (N = 20; RR 0.33, 95% CI 0.14 to 0.80; low-quality evidence) and reserpine (N = 20; RR 0.52 95% CI 0.29 to 0.96; low-quality evidence) may lead to a clinically important improvement in tardive dyskinesia symptoms compared with placebo after 2 weeks' treatment, but found no evidence of a difference between alpha-methylldopa and reserpine (N = 20; RR 0.60, 95% CI 0.19 to 1.86; very low quality evidence). Another small trial compared tetrabenazine and haloperidol after 18 weeks' treatment and found no evidence of a difference on clinically important improvement in tardive dyskinesia symptoms (N = 13; RR 0.93, 95% CI 0.45 to 1.95; very low quality evidence). No study reported on adverse events.

For remaining outcomes there was no evidence of a difference between any of the interventions: alpha-methylldopa versus placebo for deterioration of tardive dyskinesia symptoms (1 RCT; N = 20; RR 0.33, 95% CI 0.02 to 7.32; very low quality evidence), celiprolol versus placebo for leaving the study early (1 RCT; N = 35; RR 5.28, 95% CI 0.27 to 102.58; very low quality evidence) and quality of life (1 RCT; N = 35; RR 0.87, 95% CI 0.68 to 1.12; very low quality evidence), alpha-methylldopa versus reserpine for deterioration of tardive dyskinesia symptoms (1 RCT; N = 20; not estimable, no reported events; very low quality evidence), reserpine or carbidopa/levodopa versus placebo for deterioration of tardive dyskinesia symptoms (2 RCTs; N = 37; RR 1.18, 95% CI 0.35 to 3.99; very low quality evidence), oxyxpertine versus placebo for deterioration of mental state (1 RCT; N = 42; RR 2.20, 95% CI 0.22 to 22.45; very low quality evidence), dopaminergic drugs (amantadine, bromocriptine, tiapride, oxyxpertine, carbidopa/levodopa) versus placebo for leaving the study early (6 RCTs; N = 163; RR 1.29, 95% CI 0.65 to 2.54; very low quality evidence), and tetrabenazine versus haloperidol for deterioration of tardive dyskinesia symptoms (1 RCT; N = 13; RR 1.17, 95% CI 0.09 to 14.92) and leaving the study early (1 RCT; N = 13; RR 0.23, 95% CI 0.01 to 4.00).

Authors' conclusions

Although there has been a large amount of research in this area, many studies were excluded due to inherent problems in the nature of their cross-over designs. Usually data are not reported before the cross-over and the nature of TD and its likely response to treatments make it imprudent to use this data. The review provides little usable information for service users or providers and more well-designed and well-reported studies are indicated.

Plain Language Summary

Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia

Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia

Review question.

To determine if catecholaminergic drugs help in the treatment of tardive dyskinesia for people with schizophrenia or similar mental health problems.

Background.

People with schizophrenia often hear voices and see things (hallucinations) and have strange beliefs (delusions). The main treatment of schizophrenia is antipsychotic drugs. However, these drugs can have debilitating side-effects. Tardive dyskinesia is an involuntary movement that causes the face, mouth, tongue and jaw to convulse, spasm and grimace. It is caused by long-term or high-dose use of antipsychotic drugs, is difficult to treat and can be incurable. One suggested treatment is to use medication that affects the catecholaminergic system, which is a group of brain chemicals.

Study characteristics.

The review includes 10 small, short studies published mainly in the 1980s involving a total of 261 people.

Key results.

One small study found that after 2 weeks' treatment both alpha-methylldopa and reserpine may lead to clinically important improvement in tardive dyskinesia symptoms compared with placebo, but the quality of evidence was low. We are uncertain about the effect of reserpine versus alpha-methylldopa; quality of evidence was very low. Another small trial compared tetrabenazine and haloperidol after 18 weeks' treatment, but again we are uncertain about the effect as the quality of evidence was very low. The included studies did not report on any harmful effects of the drugs.
Quality of the evidence.

Evidence is weak, limited, short term, and small scale. It is not possible to recommend these drugs as a treatment for tardive dyskinesia and their use is entirely experimental. There is a need for larger and more rigorous research in the area.

This plain language summary was adapted by the review authors from a summary originally written by Ben Gray, Senior Peer Researcher, McPin Foundation (mcpin.org/).
**SUMMARY OF FINDINGS**

Summary of findings for the main comparison. NORADRENERGIC DRUGS compared to PLACEBO for antipsychotic-induced tardive dyskinesia

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of Participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assumed risk</td>
<td>Corresponding risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PLACEBO</td>
<td>NORADRENERGIC DRUGS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tardive dyskinesia: No clinically important improvement</td>
<td>1000 per 1000 (140 to 800)</td>
<td>330 per 1000</td>
<td>RR 0.33 (0.14 to 0.80)</td>
<td>20 (1 study)</td>
<td>⊕⊕⊕⊕ low¹,²</td>
</tr>
<tr>
<td></td>
<td>follow-up: 2 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tardive dyskinesia: deterioration</td>
<td>100 per 1000 (2 to 732)</td>
<td>33 per 1000</td>
<td>RR 0.33 (0.02 to 7.32)</td>
<td>20 (1 study)</td>
<td>⊕⊕⊕⊕ very low¹,³</td>
</tr>
<tr>
<td></td>
<td>follow-up: 2 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events - not reported</td>
<td></td>
<td>See comment</td>
<td>See comment</td>
<td>Not estimable</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Mental state - not reported</td>
<td></td>
<td>See comment</td>
<td>See comment</td>
<td>Not estimable</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Acceptability of treatment: Leaving the study early</td>
<td>0 per 1000 (0 to 0)</td>
<td>0 per 1000</td>
<td>RR 5.28 (0.27 to 102.58)</td>
<td>35 (1 study)</td>
<td>⊕⊕⊕⊕ very low¹,³</td>
</tr>
<tr>
<td></td>
<td>follow-up: 13 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No improvement in quality of life</td>
<td>944 per 1000 (642 to 1000)</td>
<td>822 per 1000</td>
<td>RR 0.87 (0.68 to 1.12)</td>
<td>35 (1 study)</td>
<td>⊕⊕⊕⊕ very low¹,³</td>
</tr>
<tr>
<td></td>
<td>follow-up: 13 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Summary of findings 2. NORADRENERGIC DRUGS compared to DOPAMINERGIC DRUGS for antipsychotic-induced tardive dyskinesia

**NORADRENERGIC DRUGS compared to DOPAMINERGIC DRUGS for antipsychotic-induced tardive dyskinesia**

- **Patient or population:** patients with antipsychotic-induced tardive dyskinesia
- **Setting:** inpatients in the USA
- **Intervention:** NORADRENERGIC DRUGS (alpha-methyldopa)
- **Comparison:** DOPAMINERGIC DRUGS (reserpine)

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>Nº of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tardive dyskinesia: No clinically important improvement follow-up: 2 weeks</td>
<td>Study population</td>
<td>RR 0.60 (0.19 to 1.86)</td>
<td>20 (1 study)</td>
<td>⊕⊝⊝⊝ very low¹,²</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Risk with DOPAMINERGIC DRUGS</td>
<td>500 per 1,000 (95 to 930)</td>
<td>Risk with NORADRENERGIC DRUGS</td>
<td>300 per 1,000 (95 to 930)</td>
<td></td>
</tr>
<tr>
<td>Tardive dyskinesia: Deterioration follow-up: 2 weeks</td>
<td>Study population</td>
<td>not estimable</td>
<td>20 (1 study)</td>
<td>⊕⊝⊝⊝ very low¹,³</td>
<td>Among the 20 participants no events were reported.</td>
</tr>
<tr>
<td></td>
<td>Risk with DOPAMINERGIC DRUGS</td>
<td>0 per 1,000 (0 to 0)</td>
<td>Risk with NORADRENERGIC DRUGS</td>
<td>0 per 1,000 (0 to 0)</td>
<td></td>
</tr>
<tr>
<td>Adverse events - not reported</td>
<td>See comment</td>
<td>See comment</td>
<td>not estimable</td>
<td>0 (0)</td>
<td>See comment</td>
</tr>
</tbody>
</table>
Mental state
- not reported

Acceptability of treatment: Leaving the study early
- not reported

Social confidence, social inclusion, social networks, or personalised quality of life - not reported

We found no studies reporting on this outcome.

The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1 Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately.
2 Downgraded two steps for imprecision: few events, very small sample size, and wide CI that includes both appreciable benefit and appreciable harm for intervention group as well as no effect.
3 Downgraded two steps for imprecision: no events were reported, effect estimate cannot be calculated.

Summary of findings 3. DOPAMINERGIC DRUGS compared to PLACEBO for antipsychotic-induced tardive dyskinesia

DOPAMINERGIC DRUGS compared to PLACEBO for antipsychotic-induced tardive dyskinesia

Patient or population: patients with antipsychotic-induced tardive dyskinesia
Settings: inpatients in the UK and the USA
Intervention: DOPAMINERGIC DRUGS (carbidopa/levodopa, oxypertine, reserpine)
Comparison: PLACEBO

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of Participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assumed risk</td>
<td>Corresponding risk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PLACEBO</td>
<td>DOPAMIN-ERGIC DRUGS</td>
<td>RR</td>
<td>95% CI</td>
<td>Number</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>--------------</td>
<td>---------------------</td>
<td>-------</td>
<td>--------</td>
<td>--------</td>
</tr>
<tr>
<td><strong>Tardive dyskinesia: No clinically important improvement</strong></td>
<td>1000 per 1000 (290 to 960)</td>
<td>520 per 1000 (290 to 960)</td>
<td><strong>RR 0.52</strong></td>
<td>(0.29 to 0.96)</td>
<td><strong>20</strong> (1 study)</td>
</tr>
<tr>
<td>follow-up: 2 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tardive dyskinesia: Deterioration</strong></td>
<td>167 per 1000 (58 to 665)</td>
<td>197 per 1000 (58 to 665)</td>
<td><strong>RR 1.18</strong></td>
<td>(0.35 to 3.99)</td>
<td><strong>37</strong> (2 studies)</td>
</tr>
<tr>
<td>follow-up: 2-6 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adverse events - not reported</strong></td>
<td>See comment</td>
<td>See comment</td>
<td>Not estimable</td>
<td>0 (0)</td>
<td>See comment</td>
</tr>
<tr>
<td><strong>General mental state: Deterioration</strong></td>
<td>45 per 1000 (10 to 1000)</td>
<td>100 per 1000 (10 to 1000)</td>
<td><strong>RR 2.2</strong></td>
<td>(0.22 to 22.45)</td>
<td><strong>42</strong> (1 study)</td>
</tr>
<tr>
<td>follow-up: 24 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Acceptability of treatment: Leaving the study early</strong></td>
<td>111 per 1000 (72 to 282)</td>
<td>143 per 1000 (72 to 282)</td>
<td><strong>RR 1.29</strong></td>
<td>(0.65 to 2.54)</td>
<td><strong>163</strong> (6 studies)</td>
</tr>
<tr>
<td>follow-up: 2-24 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Social confidence, social inclusion, social networks, or personalised quality of life - not reported</strong></td>
<td>See comment</td>
<td>See comment</td>
<td>Not estimable</td>
<td>0 (0)</td>
<td>See comment</td>
</tr>
</tbody>
</table>

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  
CI: Confidence interval; RR: Risk ratio;*  

**GRADE Working Group grades of evidence**  
**High quality**: Further research is very unlikely to change our confidence in the estimate of effect.  
**Moderate quality**: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  
**Low quality**: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  
**Very low quality**: We are very uncertain about the estimate.  

<sup>1</sup> Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately, blinding of outcome assessors was not described.  
<sup>2</sup> Downgraded one step for imprecision: few events and small sample size.
**Summary of findings 4. DOPAMINERGIC DRUGS compared to OTHER DRUGS for antipsychotic-induced tardive dyskinesia**

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>N° of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
</table>
|                                   | Risk with OTHER DRUGS | Risk with DOPAMINERGIC DRUGS | RR 0.93 (0.45 to 1.95) | 13 (1 study) | ⊕⊕⊕⊕ very low1,2 | **Tardive dyskinesia: No clinically important improvement**
| follow-up: 18 weeks              | Study population | 714 per 1000 | 664 per 1000 (321 to 1000) | | | **Tardive dyskinesia: Deterioration**
| follow-up: 18 weeks              | Study population | 143 per 1000 | 167 per 1000 (13 to 1,000) | RR 1.17 (0.09 to 14.92) | 13 (1 study) | ⊕⊕⊕⊕ very low1,2 |
| Adverse events                    | See comment | See comment | not estimable | 0 (0) | See comment | We found no studies reporting on this outcome. |
| - not reported                    | | | | | | |
| Mental state                      | See comment | See comment | not estimable | 0 (0) | See comment | We found no studies reporting on this outcome. |
| - not reported                    | | | | | | |
| Acceptability of treatment: Leaving the study early | Study population | 286 per 1000 | 66 per 1000 (3 to 1,000) | RR 0.23 (0.01 to 4.00) | 13 (1 study) | ⊕⊕⊕⊕ very low1,2 |
Social confidence, social inclusion, social networks, or personalised quality of life - not reported

See comment  See comment  not estimable  0 (0)  See comment  We found no studies reporting on this outcome.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

1 Downgraded one step for risk of bias: unclear whether randomisation procedure and allocation concealment were carried out adequately.
2 Downgraded two steps for imprecision: few events, very small sample size, and wide CI that includes both appreciable benefit and appreciable harm for intervention group as well as no effect.
**BACKGROUND**

**Description of the condition**

Since the 1950s, antipsychotic (or neuroleptic) medication has been extensively used to treat people with chronic mental illnesses, such as schizophrenia. These drugs can effectively control symptoms such as abnormal perceptions (hallucinations), disordered thinking and fixed false beliefs (delusions). In addition, maintenance therapy with antipsychotics is associated with a reduced risk of relapses (Schooler 1993). Antipsychotic medication, however, has also been associated with a wide range of adverse effects, including movement disorders. The appearance of these movement disorders can contribute to poor compliance with antipsychotic treatment and hence relapse (Barnes 1993).

Tardive dyskinesia (TD) is one such movement disorder and is characterised by abnormal, repetitive and involuntary movements (APA 1992). The clinical features include tongue protrusion, side-to-side or rotatory movement of the jaw, lip smacking, puckering and pursing, and rapid eye blinking (Casey 1994). In some people rapid movements of the arms, legs, and trunk may also occur. TD is a chronic condition of insidious onset, the severity of which spontaneously fluctuates (APA 1992). Studies on the natural history of tardive dyskinesia have reported widely variable remission rates (1% to 62%) depending on patient age, psychiatric diagnosis, course of the psychiatric disorder, and duration of therapy (Bergen 1989; Fernandez 2001; Glazer 1990).

Although the most frequent cause of TD is the use of antipsychotic medication, it is clinically striking that dose reduction can lead to a temporary exacerbation in symptoms. Conversely, increasing the dose is often associated with a temporary remission (Cavallaro 1993; Smith 1980). The exact mechanisms of the pathophysiology of TD are unknown. Antipsychotic drugs block certain chemical receptor sites in the brain — one of these is specific for dopamine (Casey 1994). One hypothesis explaining the cause of antipsychotic-induced TD is that chronic blockade of dopamine receptors in specific cells of the brain (neurons from the nigrostriatum) causes an overgrowth of these receptors (Casey 1994). There is also suggestion that the chronic use of antipsychotics may also cause an abnormal production of highly active atoms and chemical groups (cytotoxic free radicals), which may damage specific cells in the brain. This, in turn, could be responsible for the appearance of TD (Cadet 1989; Sachdev 2000).

TD occurs in more than 20% of those using antipsychotic medication continually for longer than three months (Glazer 2000; Kane 1982; Tarsy 2011). Every year 4% to 5% of adults and 25% to 30% of elderly persons who continually use these drugs begin to show signs of TD (APA 1992; Correll 2004). Advancing age is a risk factor for both TD’s prevalence and severity, with those who are under 60 years of age being three times more likely to spontaneously remit (Jeste 2000; Smith 1980).

The prevalence of tardive dyskinesia is often thought to be decreasing based on the use of atypical antipsychotics in place of typical antipsychotics (Cloud 2014). A systematic review found that the incidence of tardive dyskinesia associated with atypical drugs (2% to 4%) was significantly lower than that for typicals (5% to 8%) (Correll 2008). Despite this, the widespread use of atypical drugs in clinical settings, increased off-label use, and an ageing population may still result in an overall increase in the number of cases of TD (Cloud 2014; Glazer 2000; Maher 2012). The problem will be considerably greater for people in countries where use of newer drugs is less prevalent (Ballesteros 2000; Martins 2011).

**Description of the intervention**

Catecholamines occur naturally in the body. They are synthesised from the amino acid tyrosine, and examples include epinephrine (adrenaline), norepinephrine and dopamine. There are several pharmaceutical compounds acting as catecholamine analogues that have been tested as treatment for tardive dyskinesia, especially during the 1980s (Jeste 1988). This review will present data on pharmaceutical compounds affecting catecholaminergic pathways in different ways.

The catecholaminergic systems involve a complex cascade of steps that can be modified by pharmaceutical compounds at various junctures. Several strategies have been examined in the treatment of TD. These include: i. increasing the presynaptic release of dopamine (e.g. amantadine); ii. increasing the production of dopamine (e.g. L-dopa); iii. dopamine receptor antagonists (e.g. alpha-methyl-paratyrosine (AMTP)); iv. dopamine receptor agonists (e.g. apomorphine); v. agents that deplete dopamine (e.g. tetrabenazine); vi. agents that block the beta-adrenergic receptors (e.g. propanol); vii. agents that act as ‘false neurotransmitters’ (e.g. methyltyrosine) (see Types of interventions for the full list of drugs).

**How the intervention might work**

One of the most influential theories to explain the appearance of TD suggests that long-term use of antipsychotic medication leads to an increase in the number of dopamine and dopamine-related receptors. This hypothesis is usually referred to as the dopamine supersensitivity theory (Browne 1986b; Casey 1994); and hence drugs that influence the catecholaminergic (noradrenergic and dopaminergic) function in the extrapyramidal system have been used as treatments for antipsychotic-induced TD. It was thought that these compounds could reverse dopamine supersensitivity by increasing the levels of available dopamine, thus overcoming the antipsychotic-induced dopamine blockade (Friedhoff 1977).

Currently, however, there is no clear evidence of the effectiveness of these drugs in treating TD. Nevertheless, they have been associated with many side effects, including drowsiness, confusion, postural hypotension, depression and worsening of psychosis (Turjanski 2005). In addition, an excess of dopamine has itself been associated with movement disorders (choreoathetoid).

**Why it is important to do this review**

Several atypical antipsychotic drugs have been produced in the last decades that claim to cause less or no TD (Lieberman 1996). These claims may or may not be true, and certainly evidence does point to the fact that thoughtful use of older-generation drugs is not associated with any more problems of TD than are newer treatments (Chouinard 2008). However, in a global context, it is likely that the less expensive and more familiar drugs — such as chlorpromazine or haloperidol — will continue to be the mainstay of treatment of people with schizophrenia (WHO Essential List 2010). Use of drugs such as these is associated with emergence of TD and, therefore, this condition will remain a problem for years to come.
TD can result in considerable social and physical disability (Barnes 1993); and symptoms are often irreversible (Bergen 1989; Fernandez 2001; Glazer 1990). Additionally, TD is frequently associated with lower quality of life (Ascher-Svanum 2008); and a greater mortality rate (Chong 2009). Given the high incidence and prevalence of TD among people taking antipsychotic medication, the need for prevention or treatment is clear. Unfortunately, there has been sparse evidence to guide clinicians (NICE 2014; Taylor 2009). Although many treatments have been tested, no one intervention has been shown clearly to be effective. Cessation or reduction of the dose of antipsychotic medication would be the ideal management for TD. In clinical practice this is not always possible, not least because in many individuals such a reduction would lead to relapse. This review focuses on whether the addition of different types of catecholaminergic medications to those already receiving antipsychotic medication is likely to help TD.

This review is one in a series of Cochrane Reviews evaluating treatments for antipsychotic-induced TD (see Table 1), and is an update of a Cochrane Review first published in 2006 (El-Sayeh 2006).

OBJECTIVES

1. To determine the effects of any of the following drugs for antipsychotic-induced TD in people with schizophrenia or other chronic mental illnesses.
   i. Drugs which influence the noradrenergic system.
   ii. Dopamine receptor agonists.
   iii. Dopamine receptor antagonists.
   iv. Dopamine-depleter drugs.
   v. Drugs that increase the production or release of dopamine.

2. To examine whether any improvement occurred with short periods of intervention (less than 6 weeks) and, if this did occur, whether this effect was maintained at longer periods of follow-up.

3. To examine if there was a differential effect for the various compounds.

4. To examine whether the use of non-antipsychotic catecholaminergic drugs are most effective in those with more recent onset TD (less than five years).

METHODS

Criteria for considering studies for this review

Types of studies

We included all relevant randomised controlled trials. Where a trial was described as 'double-blind' but it was implied that the study was randomised, we included these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes (see Types of outcome measures) when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only used clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.

Types of participants

People with schizophrenia or any other chronic mental illness, diagnosed by any criteria, irrespective of gender, age or nationality who:

i. required the use of antipsychotics for more than three months;
ii. developed tardive dyskinesia (diagnosed by any criteria) during antipsychotic treatment; and
iii. for whom the dose of antipsychotic medication had been stable for one month or more before the trial (the same applies for those free of antipsychotics).

Types of interventions

A. Noradrenergic drugs

i. Celiprolol, clonidine, disulfiram, fusaric acid, methylpopa, pindolol, propanolol, oxprenolol or yohimbin, compared with placebo or no intervention. For the 2017 update a post hoc decision was made to also include studies evaluating the above-mentioned noradrenergic drugs compared to any other intervention for the treatment of tardive dyskinesia.

B. Dopaminergic drugs

i. The dopamine receptor agonists (apomorphine, bromocriptine, CF25-397, dopamine, hyderygine, lisuride);
ii. the dopamine receptor antagonists (AMTP, oxiperomide, metoclopramide, papaverine, tiapride);
iii. the dopamine-depleting drugs (oxypertine, reserpin, tetrabenazine);
iv. drugs that increase the release (amantadine, amphetamine) or production (L-dopa) of dopamine; all compared with placebo or no intervention. For the 2017 update a post hoc decision was made to also include studies evaluating the above mentioned dopaminergic drugs compared to any other intervention for the treatment of tardive dyskinesia.

Types of outcome measures

We have defined clinical efficacy as an improvement in the symptoms of TD of more than 50%, on any scale. We grouped outcomes into short term (less than six weeks), medium term (between six weeks and six months) and long term (more than six months).

Primary outcomes

1. Tardive dyskinesia

No clinically important improvement in the symptoms of individuals, defined as more than 50% improvement on any tardive dyskinesia scale – any time period.

2. Adverse effects

No clinically significant extrapyramidal adverse effects – any time period.

Secondary outcomes

1. Tardive dyskinesia (TD)

1.1 Any improvement in the symptoms of individuals on any TD scale, as opposed to no improvement.
1.2 Deterioration in the symptoms of individuals, defined as any deleterious change on any TD scale.
1.3 Average change in severity of TD during the trial period.
1.4 Average difference in severity of TD at the end of the trial.

2. General mental state changes
2.1 Deterioration in general psychiatric symptoms (such as delusions and hallucinations) defined as any deleterious change on any scale.
2.2 Average difference in severity of psychiatric symptoms at the end of the trial.

3. Acceptability of the treatment
3.1 Acceptability of the intervention to the participant group as measured by numbers of people dropping out during the trial.

4. Adverse effects
4.1 Use of any anti-parkinsonism drugs.
4.2 Average score/change in extrapyramidal adverse effects.
4.3 Acute dystonia.

5. Other adverse effects, general and specific
6. Hospital and service utilisation outcomes
6.1 Hospital admission.
6.2 Average change in days in hospital.
6.3 Improvement in hospital status (for example: change from formal to informal admission status, use of seclusion, level of observation).

7. Economic outcomes
7.1 Average change in total cost of medical and mental health care.
7.2 Total indirect and direct costs.

8. Social confidence, social inclusion, social networks, or personalised quality of life measures
8.1. No significant change in social confidence, social inclusion, social networks, or personalised quality of life measures.
8.2 Average score/change in social confidence, social inclusion, social networks, or personalised quality of life measures.

9. Behaviour
9.1 Clinically significant agitation.
9.2 Use of adjunctive medication for sedation.
9.3 Aggression to self or others.

10. Cognitive state
10.1 No clinically important change.
10.2 No change, general and specific.

'Summary of findings' table
We used the GRADE approach to interpret findings (Schünemann 2011) and used GRADEpro to export data from this review to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effects of interventions examined and the sum of available data on all outcomes rated as important to patient care and decision making. This summary was used to guide our conclusions. We selected the following main outcomes for inclusion in the 'Summary of findings' table.

1. Tardive dyskinesia
   1.1 Improved to a clinically important extent
   1.2 Deteriorated

2. Mental state
   2.1 Deteriorated

3. Adverse effect
   3.1 Any adverse event
   3.2 Adverse effects: no clinically significant extrapyramidal adverse effects

4. Acceptability of treatment
   4.1 Leaving the study early

5. Social confidence, social inclusion, social networks, or personalised quality of life measures*
   5.1 No significant change in social confidence, social inclusion, social networks, or personalised quality of life measures for either recipients of care or caregivers

* Outcome designated important to patients. We wished to add perspectives from people's personal experience with TD to the research agenda. A consultation with service users was planned where the previously published version of another review in the tardive dyskinesia series and a lay overview of that review gave the foundation for the discussions (Soares-Weiser 2011; Table 1). The session was planned to provide time to reflect on current research on TD and consider gaps in knowledge. The report is published in the Health Technology Assessment (HTA) report for the UK National Institute of Health Research (Appendix 1, Bergman 2017). We have added one figure showing a service user's expression of frustration concerning this neglected area of research (Figure 1). Informed by the results of the consultation, for this review we updated outcomes for the 'Summary of findings' table.
Figure 1. Message from one of the participants of the Public and patient involvement consultation of service user perspectives on tardive dyskinesia research.

Search methods for identification of studies

Electronic searches

The 2017 review update was carried out in parallel with updating eight other TD reviews; see Table 1 for details. The search covered all nine tardive dyskinesia reviews.

1. Cochrane Schizophrenia Group’s Register

We searched Cochrane Schizophrenia Group’s Study-Based Register of Trials on 16 July 2015 and 26 April 2017 using the following string: "Tardive Dyskinesia" in Healthcare Condition Field of Study. In a study-based register such as this, searching the major concept retrieves all the synonym keywords and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics. The Cochrane Schizophrenia Group’s Register of Trials is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see Group’s Module). There is no language, date, document type, or publication status limitations for inclusion of records into the register.

3. Details of previous electronic searches

See Appendix 1.

Searching other resources

1. Reference searching

We inspected references of all identified studies for further relevant studies.

2. Personal contact

We contacted the first author of each included study for information regarding unpublished trials.

Data collection and analysis

Selection of studies

For the 2017 update, reviewers RA and AG (see Acknowledgements) inspected all abstracts of studies identified as above and identified potentially relevant reports. We resolved disagreement by discussion, or where there was still doubt, we acquired the full article for further inspection. We acquired the full articles of relevant reports/abstracts meeting initial criteria for reassessment and carefully inspected for a final decision on inclusion (see Criteria for considering studies for this review). RA and AG were not blinded to the names of the authors, institutions or journal of publication. Where difficulties or disputes arose, we asked author HB for help and where it was impossible to decide or if adequate information was not available to make a decision, we added these studies to those awaiting assessment and contacted the authors of the papers for clarification.

Data extraction and management

1. Extraction

For the 2017 update, reviewers RA and HB independently extracted data from all included studies. Again, we discussed any disagreement and documented decisions. With remaining problems KSW helped clarify issues and we documented these final decisions. We extracted data presented only in graphs and figures whenever possible, but included only if two reviewers independently had the same result. We attempted to contact...
authors through an open-ended request in order to obtain missing information or for clarification whenever necessary. If studies were multi-centre, where possible we extracted data relevant to each component centre separately.

2. Management

2.1 Forms

For the 2017 update we extracted data online in Covidence. Extracted data are available here with a link to the original source PDF for each item.

2.2 Scale-derived data

We included continuous data from rating scales only if:

a) the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (Marshall 2000); and

b) the measuring instrument has not been written or modified by one of the trialists for that particular trial.

Ideally the measuring instrument should either be i. a self-report or
ii. completed by an independent rater or relative (not the therapist).
We realise that this is not often reported clearly; we noted in Description of studies if this was the case or not.

2.3 Endpoint versus change data

There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult-to-measure conditions such as schizophrenia. We decided to primarily use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we preferred to use mean differences (MD) rather than standardised mean differences throughout (Higgins 2011).

2.4 Skewed data

Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we applied the following standards to relevant data before inclusion (see (a), (b) and (c) below).

Please note: we entered data from studies of at least 200 participants in the analysis, because skewed data pose less of a problem in large studies. We also entered all relevant change data as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not.

For endpoint data from studies with fewer than 200 participants:

(a) when a scale starts from the finite number zero, we subtracted the lowest possible value from the mean, and divided this by the standard deviation. If this value was lower than 1, it strongly suggests a skew and we excluded these data. If this ratio was higher than 1 but below 2, there is suggestion of skew. We entered these data and tested whether their inclusion or exclusion changed the results substantially. Finally, if the ratio was larger than 2 we included these data, because skew is less likely (Altman 1996; Higgins 2011).

(b) if a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS) (Kay 1986), which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if $2 SD > (S - S_{min})$, where $S$ is the mean score and '$S_{min}$' is the minimum score.

2.5 Common measure

Where relevant, to facilitate comparison between trials we converted variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).

2.6 Conversion of continuous to binary

Where possible, we converted continuous outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962) or the Positive and Negative Syndrome Scale (PANSS, Kay 1986), this can be considered as a clinically significant response (Leucht 2005a; Leucht 2005b). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.

Assessment of risk of bias in included studies

Reviewers RA (see Acknowledgements) and HB independently assessed risk of bias within the included studies by using criteria described in the Cochrane Handbook for Systematic Reviews of Interventions to assess trial quality (Higgins 2011). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.

If the raters disagreed, we made the final rating by consensus, with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain further information. If non-concurrency occurred, we reported this.

We noted the level of risk of bias in the text of the review and in Figure 2, Figure 3, Summary of findings for the main comparison and Summary of findings 3.
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figure 2. (Continued)

Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Measures of treatment effect

1. Binary data
For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive than odds ratios (Boissel 1999), as odds ratios tend to be interpreted as RR by clinicians (Deeks 2000).

2. Continuous data
For continuous outcomes we estimated mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we presumed there is a small difference in measurement, and calculated effect size and transformed the effect back to the units of one or more of the specific instruments.

Unit of analysis issues

1. Cluster trials
Studies increasingly employ ‘cluster randomisation’ (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra-class correlation in clustered studies, leading to a ‘unit of analysis’ error whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated (Divine 1992). This causes type I errors (Bland 1997; Gulliford 1999). If any of the included trials had randomised participants by clusters, and where clustering is not accounted for in primary studies, we would have presented such data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation coefficients for their clustered data and to adjust for this by using accepted methods (Gulliford 1999). Where clustering has been incorporated into the analysis of primary studies, we will present these data as if from a non-cluster randomised study, but adjust for the clustering effect.

We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a ‘design effect’. This is calculated using the mean number of participants per cluster (m) and the intra-class correlation coefficient (ICC) (Design effect = 1 + (m − 1) * ICC (Donner 2002)). If the ICC is not reported it will be assumed to be 0.1 (Ukoumunne 1999).

If cluster studies have been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse variance technique.

2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It occurs if an effect (pharmaceutical, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (Elbourne 2002). As both effects are very likely in severe mental illness, we only used data of the first phase of cross-over studies.

Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia (Review)
3. Studies with multiple treatment groups

Where a study involves more than two treatment arms, if relevant we presented the additional treatment arms in comparisons. If data were binary we simply added and combined within the two-by-two table. If data were continuous we combined data following the formula in section 7.7.3.8 (Combining groups) of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We did not use data where the additional treatment arms were not relevant.

Dealing with missing data

1. Overall loss of credibility

At some degree of loss to follow-up, data must lose credibility (Xia 2009). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we addressed this within the ‘Summary of findings’ table/s by down-rating quality. We also downgraded quality within the ‘Summary of findings’ table/s should loss be 25% to 50% in total.

2. Binary

In the case where attrition for a binary outcome is between 0% and 50% and where these data are not clearly described, we presented data on a ‘once-randomised-always-analyse’ basis (an intention-to-treat analysis). We assumed all those leaving the study early had no improvement. We undertook a sensitivity analysis testing how prone the primary outcomes were to change by comparing data only from people who completed the study to that point to the intention-to-treat analysis using the above assumptions.

3. Continuous

3.1 Attrition

We reported and used data where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported.

3.2 Standard deviations

If standard deviations were not reported, we first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error and confidence intervals available for group means, and either P value or t value available for differences in mean, we calculated them according to the rules described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011): when only the standard error (SE) is reported, standard deviations (SDs) are calculated by the formula SD = SE * √(n). Chapters 7.7.3 and 16.1.3 of the Cochrane Handbook for Systematic Reviews of Interventions present detailed formulae for estimating SDs from P, t or F values, confidence intervals, ranges or other statistics (Higgins 2011). If these formulae did not apply, we calculated the SDs according to a validated imputation method which is based on the SDs of the other included studies (Furukawa 2006). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values.

3.3 Assumptions about participants who left the trials early or were lost to follow-up

Various methods are available to account for participants who left the trials early or were lost to follow-up. Some trials just present the results of study completers; others use the method of last observation carried forward (LOCF); while more recently, methods such as ‘multiple imputation’ or ‘mixed effects’ models for repeated measurements (MMRM) have become more of a standard. While the last two methods seem to be somewhat better than LOCF (Leon 2006), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia trials. We therefore did not exclude studies which used the statistical approach. However, we preferred to use the more sophisticated approaches (e.g. MMRM or ‘multiple imputation’) and only presented completer analyses if some kind of ITT data were not available at all. Moreover, we addressed this issue in the item ‘Incomplete outcome data’ of the ‘Risk of bias’ tool.

Assessment of heterogeneity

1. Clinical heterogeneity

We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise; and discussed in the text if they arose.

2. Methodological heterogeneity

We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise; and discussed in the text if they arose.

3. Statistical heterogeneity

3.1 Visual inspection

We visually inspected graphs to investigate the possibility of statistical heterogeneity.

3.2 Employing the I² statistic

We investigated heterogeneity between studies by considering the $I^2$ method alongside the $\chi^2$ P value. The $I^2$ provides an estimate of the percentage of inconsistency thought to be due to chance (Higgins 2003). The importance of the observed value of $I^2$ depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from $\chi^2$ test, or a confidence interval for $I^2$). An $I^2$ estimate greater than or equal to around 50% accompanied by a statistically significant $\chi^2$ statistic can be interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 Cochrane Handbook for Systematic Reviews of Interventions; Higgins 2011). We explored and discussed in the text potential reasons for substantial levels of heterogeneity (Subgroup analysis and investigation of heterogeneity).

Assessment of reporting biases

Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (Egger 1997). These are described in Section 10 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We are aware
that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there are 10 or fewer studies, or where all studies were of similar sizes. If funnel plots are possible in future versions of this review, we will seek statistical advice in their interpretation.

Data synthesis

We understand that there is no closed argument for fixed-effect over random-effects models, or vice versa. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect these studies can either inflate or deflate the effect size. We chose the fixed-effect model for all analyses.

Subgroup analysis and investigation of heterogeneity

1. Subgroup analyses

1.1 Type of compound

As different non-antipsychotic catecholaminergic compounds may have differential effects on antipsychotic-induced tardive dyskinesia, we performed a subgroup analysis to compare the effects of different non-antipsychotic catecholaminergic drugs. We proposed to undertake comparisons only for primary outcomes to minimise the risk of multiple comparisons.

1.2 Duration of treatment

We also anticipated a sub-group analysis to examine whether any improvement occurred with short periods of intervention (less than six weeks); and if this did occur, whether this effect was maintained at longer periods of follow-up.

1.3 Clinical state, stage or problem: recent onset TD

We proposed to undertake this review and provide an overview of the effects of non-antipsychotic catecholaminergic drugs for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems. We anticipated testing the hypothesis that the use of non-antipsychotic catecholaminergic drugs is most effective for those with more recent onset TD (less than five years). We had hoped to present data for this subgroup for the primary outcomes.

2. Investigation of heterogeneity

We reported when inconsistency was high. First we investigated whether data were entered correctly. Second, if data were correct, we visually inspected the graph and successively removed studies from the rest to see if homogeneity was restored. For this review we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present data. If not, we did not pool such data and discussed issues. We know of no supporting research for this 10% cut-off but we are investigating use of prediction intervals as an alternative to this unsatisfactory state.

When unanticipated clinical or methodological heterogeneity were obvious, we simply discussed. We did not undertake sensitivity analyses relating to these.

Sensitivity analysis

1. Implication of randomisation

If trials were described in some way as to imply randomisation we undertook sensitivity analyses for the primary outcomes. We included these studies in the analyses and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we used relevant data from these studies.

2. Assumptions for lost binary data

Where assumptions had to be made regarding people lost to follow-up (see Dealing with missing data) we compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there was a substantial difference, we reported and discussed these results but continued to employ our assumption.

Where assumptions have to be made regarding missing SDs data (see Dealing with missing data), we compared the findings on primary outcomes when we used our assumption with completer data only. We undertook a sensitivity analysis, testing how prone results were to change when ‘completer’ data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported and discussed these results but continued to employ our assumption.

3. Risk of bias

We analysed the effects of excluding trials that we judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available), allocation concealment, blinding and outcome reporting for the meta-analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, we included data from these trials in the analysis.

4. Imputed values

Had cluster trials been included, we would have undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect.

If we found substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately.

5. Fixed and random effects

We synthesised data using a fixed-effect model; however, we also synthesised data for the primary outcome using a random-effects model to evaluate whether this altered the significance of the results.
RESULTS

Description of studies

Please see Characteristics of included studies, Characteristics of excluded studies and Characteristics of studies awaiting classification.

Results of the search

The 2015 and 2017 update searches were part of an update search of nine Cochrane Reviews; see Table 1. The 2015 search retrieved 704 references for 344 studies; see Figure 4 for study flow diagram. After having excluded irrelevant references at title and abstract screening, we screened full texts of 71 references (58 studies). Forty-eight studies (57 references) were excluded, and 29 of these are new excluded studies for the 2017 update. Two studies were awaiting assessment in the previous version of the review and have since been assessed in Chinese and Portuguese, found to have met inclusion criteria, and included (Chen 1995; Karniol 1983). Another six new studies were included from the 2015 search (Huang 1981; Kazamatsuri 1973; Pappa 2010; Rust 1984; Simpson 1988; Soni 1986). Ten studies are now included in this review.
Figure 4. Study flow diagram for 2015 and 2017 searching

704 records identified through database searching

10 additional records identified through reference lists of tardive dyskinesia Cochrane reviews

8 records found from searching in 2017

722 records after duplicates removed

722 records screened

651 records excluded

57 full-text articles (48 studies) excluded, with reasons

71 full-text articles assessed for eligibility

10 studies (14 references) included in qualitative synthesis

10 studies (14)
The 2017 search found eight records (five studies). The Editorial base of Cochrane Schizophrenia screened these records and no new studies were relevant to this review. They could be relevant to the other reviews in this series of TD reviews (see Table 1), and have been put into 'Studies awaiting classification' of the Soares-Weiser 2006 miscellaneous treatments review.

Included studies
Overall the review now includes 10 studies with 261 participants published between 1973 and 2010. Eight of these studies were added at the 2017 update (Chen 1995; Huang 1981; Karniol 1983; Kazamatsuri 1973; Pappa 2010; Rust 1984; Simpson 1988; Soni 1986).

1. Methods
All studies were stated to be randomised and double blind. For further details, please see sections below on Allocation (selection bias) and Blinding (performance bias and detection bias).

2. Design
All included studies presented a parallel longitudinal design. Three of the 10 studies used a cross-over design with two periods (Buruma 1982; Chen 1995; Pappa 2010). We had considered this possibility when embarking on the review and have used only the data from before the first cross-over for the reasons outlined above (see Unit of analysis issues).

3. Duration
Treatment phases of five studies were of short duration (2 to 5 weeks) (Buruma 1982; Chen 1995; Huang 1981; Karniol 1983; Pappa 2010); and treatment phases of the remaining five studies were of medium duration (6 to 24 weeks) (Hebbenstreit 1986; Kazamatsuri 1973; Rust 1984; Simpson 1988; Soni 1986).

4. Participants
Participants, now totalling 261 people, were mostly men in their 50s, with diagnoses of various chronic psychiatric disorders, but mainly schizophrenia. All had antipsychotic-induced tardive dyskinesia (TD), though only four studies reported the specific diagnostic criteria used (Hebbenstreit 1986; Pappa 2010; Simpson 1988; Soni 1986). The number of participants ranged from 12 to 50 (median 21).

5. Setting
One trial was conducted with outpatients in Greece (Pappa 2010); and the rest with psychiatric inpatients in the USA (Huang 1981; Kazamatsuri 1973; Simpson 1988), Austria (Hebbenstreit 1986), Brazil (Karniol 1983), China (Chen 1995), France (Rust 1984), the Netherlands (Buruma 1982), and the UK (Soni 1986).

6. Interventions
6.1 Noradrenergic drugs
6.1.1 Alpha-methyldopa
Huang 1981 used alpha-methyldopa in a dose ranging from 750 to 1500 mg/day. Methyldopa inhibits dopamine production and is also an adrenergic receptor agonist, and is used to treat hypertension and pregnancy-induced hypertension.

6.1.2 Celiprolol
Hebbenstreit 1986 used celiprolol in a 200 mg/day dose. Celiprolol is a cardioselective beta blocker reported to possess intrinsic sympathomimetic activity and direct vasodilator activity. Celiprolol is used as the hydrochloride in the management of hypertension and angina pectoris.

6.2 Dopaminergic drugs
6.2.1 Amantadine
Pappa 2010 used amantadine in a dose of 100 mg/day. Amantadine is a glutamate receptor antagonist and anticholinergic that increases dopamine release and blocks dopamine reuptake. It can be used both as an antiviral and antiparkinsonian drug.

6.2.2 Bromocriptine
Chen 1995 used bromocriptine one capsule twice per day (exact dose unknown). Bromocriptine is a dopamine agonist used to treat various conditions including pituitary tumours, Parkinson’s disease, type 2 diabetes, and cocaine withdrawal.

6.2.3 Carbidopa/levodopa (L-dopa)
Simpson 1988 used carbidopa/levodopa in a dose of 50/350 mg/day. Karniol 1983 used levodopa in a dose ranging from 500 mg to 2000 mg. Carbidopa is used in Parkinson’s disease in combination with levodopa to make levodopa more accessible. L-dopa is the precursor to the catecholaminergic neurotransmitters dopamine, noradrenaline and adrenaline. L-dopa can also be manufactured and is used as a drug to treat Parkinson’s disease.

6.2.4 Oxypertine
Soni 1986 used oxypertine in a dose ranging from 80 mg/day to 240 mg/day. Oxypertine is a dopamine depleter drug used...
in the treatment of mania, disturbed behaviour, psychosis and schizophrenia.

6.2.5 Reserpine

Huang 1981 used reserpine in a dose ranging from 0.75 to 1.5 mg/day. Reserpine is a dopamine depleter drug that has been used in the past to treat psychosis and hypertension. Today it is mainly used as a horse tranquilliser.

6.2.6 Tetrabenazine

Kazamatsuri 1973 used tetrabenazine in a dose ranging from 50 mg to 200 mg/day. Tetrabenazine is a dopamine depleter drug approved to treat symptoms of Huntington’s disease chorea.

6.2.7 Tiapride

Two studies used tiapride in a dose ranging from 300 mg to 600 mg/day (Buruma 1982; Rust 1984). Tiapride is a substituted benzamide with general properties similar to those of the antipsychotic sulphuride. It is usually given as the hydrochloride in the management of behavioural disorders and to treat dyskinesias. Tiapride has been tried in the treatment of Tourette’s syndrome and chorea such as Huntington’s chorea.

6.3 Comparison group

In most of the studies a placebo was used as a comparison group, with no further details given. In one study the comparison group was haloperidol (Kazamatsuri 1973). Another trial compared groups with different doses of L-dopa and placebo (Karniol 1983); and Huang 1981 included three arms: celiprolol (noradrenergic), reserpine (dopamine depleter) and placebo.

Participants remained on stable schizophrenia treatment antipsychotic medication during the trials.

7. Outcomes

7.1 General

Some outcomes were presented in graphs, inexact P values of differences, or a statement of significant or non-significant difference. This made it impossible to acquire raw data for synthesis. Some continuous outcomes could not be extracted due to missing number of participants or missing means, standard deviations, or standard errors.

7.2 Scales used to measure TD symptoms

We have shown details of the scales that provided usable data below. We have provided reasons for exclusions under 'Outcomes' in the Characteristics of included studies table.

7.2.1 Abnormal Involuntary Movement Scale (AIMS)

Simpson 1988 reported using AIMS to assess TD symptoms, and Hebenstreit 1986 reported using SKAUB, the German version of AIMS. The AIMS is a 12-item scale consisting of a standardised examination followed by questions rating the orofacial, extremity and trunk movements, as well as three global measurements (Guy 1976). Each of these 10 items can be scored from 0 (none) to 4 (severe). Two additional items assess dental status. The AIMS ranges from 0 to 40, with higher scores indicating greater severity.

7.2.2 Extrapyramidal Bilan scale (EBS)

Karniol 1983 used the EBS. The EBS is a nine-item rating scale for use by neurologists, to measure severity of symptoms such as facial mask, tremor, rigidity, akathisia, dystonia, dyskinesias and others (Tetreault 1969). Each item can be scored from 0 to 3, such that the overall score can range from 0 (no symptoms) to a possible 27 (severe symptoms of all types).

7.3 Clinical assessment

Two studies reported using a frequency count of mouth movements, performed by a psychiatrist, to assess oral dyskinesia (Huang 1981; Kazamatsuri 1973).

Excluded studies

There are 48 excluded studies (57 references). Thirteen studies were not randomised and we therefore excluded them (Asher 1981; Chouza 1982; Delwaide 1980; Fahn 1983; Ferrari 1972; Gerlach 1976; Kazamatsuri 1972; König 1996; Leblhuber 1987; Levy 1984; Ringwald 1978; Rondot 1987; Smith 1977). Seven RCTs did not meet inclusion criteria because they recruited participants without tardive dyskinesia (Adler 1990; DiMascio 1976; Fann 1976; Gutierrez 1979; NCT00310661 2006; NCT00845000 2009; O’Suilleabain 2003). Participants in two RCTs were not on stable antipsychotic medication before and during the study and were consequently not eligible for inclusion (Jankovic 1982; Lieberman 1989). Two RCTs evaluated selegiline, an intervention that is not relevant for this review: Goff 1993 is included in the update of the ‘Miscellaneous treatments for antipsychotic-induced tardive dyskinesia’ Cochrane Review (Soares-Weiser 2003); and Stearns 1996 also reported no usable data so was excluded from the Soares-Weiser 2003 review as well as from this review.

Twenty-four studies had to be excluded because data were all unusable, in 18 of these as a result of failure to report outcomes from the first phase before cross-over. We contacted authors of six of these 18 studies but received no reply (Doongaji 1982; Hemmani 1982; Jeste 1983; Lieberman 1988; Nasrallah 1986; Tamminga 1980); and since they were all published over 25 years ago and we assumed we would be very unlikely to receive a reply with data so many years later, they were excluded. We did not identify up-to-date contact details of authors for 12 of 18 cross-over studies and decided to also exclude them as they were published 20 to 45 years ago and again we assumed we would be very unlikely to receive a reply with data so many years later (Angus 1997; Auburger 1985; Bateman 1979; Braun 1989; Browne 1986a; Chien 1978; Delwaide 1979; Freeman 1980; Gardos 1979; Glover 1980; Godwin Austen 1971; Vukari 1975). No usable outcome data were reported in the six remaining studies. We contacted authors of Alpert 1983 and Diehl 1999 but received no reply. We could not identify up-to-date contact details for authors of Green Dyke 1988, Ludatcher 1989, Reker 1982 and Silver 1995. These six studies were also excluded as they were published 15 to 30 years ago and again we assumed we would be very unlikely to receive a reply with data so many years later. See Characteristics of excluded studies for more details on each excluded study.

Studies awaiting classification

There are currently no studies awaiting classification.
Ongoing studies
As far as we are aware, there are currently no ongoing studies.

Risk of bias in included studies
Please refer to Figure 2 and Figure 3 for graphical overviews of the risk of bias in the included studies, and Characteristics of included studies for details.

Allocation
Reporting of randomisation and allocation concealment was poor overall. No study explicitly reported the method for sequence generation other than using the word “randomized” and consequently all studies were rated at unclear risk of bias for sequence generation. Only two studies were rated at low risk of bias for allocation concealment. Chen 1995 reported the allocation of participants by an external site while Karniol 1983 used sealed opaque envelopes. The remaining studies were rated at unclear risk of bias for allocation concealment.

Blinding
Although all studies were stated to be conducted on a double-blind basis, not all explicitly described how this was undertaken and none tested the blindness of raters, clinicians and trial participants. Chen 1995, Hebenstreit 1986, Karniol 1983, Pappa 2010 and Simpson 1988 described how the participants and personnel were blinded and were rated at low risk of performance bias. Kazamatsuri 1973, Pappa 2010, and Soni 1986 described how the raters were blinded and were rated at low risk of detection bias. The remaining studies were rated at unclear risk of performance or detection bias, or both.

Incomplete outcome data
In four studies all randomised participants completed the study and were included in analyses; these were rated at low risk of attrition bias (Buruma 1982; Chen 1995; Pappa 2010; Rust 1984). Three studies did not report fully on attrition and were at unclear risk of bias (Hebenstreit 1986; Huang 1981; Karniol 1983). Three studies had 30% or greater loss to follow-up (Soni 1986), or unbalanced loss to follow-up between groups (Kazamatsuri 1973; Simpson 1988), and did not report outcomes for participants lost to follow-up. These studies were rated at high risk of attrition bias. In all cases, however, we tried to ensure that every person randomised was analysed.

Selective reporting
Data in this review originates from published reports. Expected outcomes (impact on tardive dyskinesia symptoms, adverse events) were not reported sufficiently for most of the trials. In addition, we have had no opportunity to see protocols of these trials to compare the outcomes reported in the full publications with what was planned and measured during the conduct of the trial. Three studies were rated at unclear risk of reporting bias as it was unclear whether all outcomes were fully reported (Chen 1995; Kazamatsuri 1973; Rust 1984). The remaining seven studies were at high risk of reporting bias as they failed to fully report all measured outcomes.

Other potential sources of bias
All studies had small or very small sample sizes. Three of the studies used a cross-over design (Buruma 1982; Chen 1995; Pappa 2010); four of the studies had the drugs used in the trials provided by pharmaceutical companies (Buruma 1982; Kazamatsuri 1973; Simpson 1988; Soni 1986); and in six studies no details of funding were given (Chen 1995; Hebenstreit 1986; Huang 1981; Karniol 1983; Pappa 2010; Rust 1984).

Nevertheless, we rated four studies at low risk bias as they seemed to be free from other sources of bias and baseline characteristics were balanced between groups (Chen 1995; Hebenstreit 1986; Karniol 1983; Soni 1986). Five studies were at unclear risk of other bias as insufficient information was available to make a judgement otherwise (Huang 1981; Kazamatsuri 1973; Pappa 2010; Rust 1984; Simpson 1988). Finally, Buruma 1982 was at high risk of other bias as the placebo group contained participants more severely affected by TD at baseline.

Effects of interventions
See: Summary of findings for the main comparison NORADRENERGIC DRUGS compared to PLACEBO for antipsychotic-induced tardive dyskinesia; Summary of findings 2 NORADRENERGIC DRUGS compared to DOPAMINERGIC DRUGS for antipsychotic-induced tardive dyskinesia; Summary of findings 3 DOPAMINERGIC DRUGS compared to PLACEBO for antipsychotic-induced tardive dyskinesia; Summary of findings 4 DOPAMINERGIC DRUGS compared to OTHER DRUGS for antipsychotic-induced tardive dyskinesia

1. Comparison 1: noradrenergic drugs versus placebo

1.1 TD symptoms

We had chosen ‘any improvement in TD symptoms of more than 50% on any TD scale – any time period’ as a primary outcome. Although the data we found in trials did not fit this exactly we feel that the outcome ‘not improved to a clinically important extent’ fits best with what we had hoped to find.

1.1.1 Not improved to a clinically important extent

The overall results for ‘clinically relevant improvement’ found a significant benefit of alpha-methyldopa over placebo after 2 weeks’ treatment (low-quality evidence, 1 trial, 20 people; RR 0.33, 95% CI 0.14 to 0.80; Analysis 1.1).

1.1.2 Not any improvement

For the outcome of ‘any improvement in TD symptoms’ we found no significant difference between noradrenergic drugs (alpha-methyldopa, celiprolol) and placebo after 2 to 13 weeks’ treatment (2 trials, 55 people; RR 0.91, 95% CI 0.65 to 1.27; I² = 0%, Analysis 1.2).

1.1.3 Deterioration of symptoms

There was no significant difference in deterioration of symptoms between people allocated to alpha-methyldopa or placebo after 2 weeks’ treatment (very low quality evidence, 1 trial, 20 people; RR 0.33, 95% CI 0.02 to 7.32; Analysis 1.3).

1.2 Leaving the study early

Using celiprolol did not significantly increase the chances of a person leaving the study early compared with placebo after 13 weeks’ treatment (very low quality evidence, 1 trial, 35 people; RR 5.28, 95% CI 0.27 to 102.58; Analysis 1.4).
1.3 Quality of life
There was no significant difference in quality of life between people allocated to clonipramine or placebo after 13 weeks’ treatment (very low quality evidence, 1 trial, 35 people; RR 0.87, 95% CI 0.68 to 1.12; Analysis 1.5).

We did not identify any studies that reported on hospital and service utilisation outcomes, economic outcomes, behaviour, or cognitive state.

1.4 Subgroup analysis
1.4.1 Type of compound
There were no significant subgroup differences ($I^2 = 0\%$, $P = 0.52$, Analysis 1.2) for alpha-methylaspartate versus placebo (RR 0.33, 95% CI 0.02 to 7.32; 20 participants, 1 study) and clonipramine versus placebo (RR 0.92, 95% CI 0.66 to 1.28; 35 participants, 1 study) on ‘not any improvement in TD symptoms’, the only outcome for this comparison that evaluated more than one non-antipsychotic catecholaminergic compound.

1.4.2 Duration of follow-up
Any effects that noradrenergic drugs may have did not clearly change in relation to duration of follow-up compared with placebo.

1.4.3 Clinical stage: recent onset TD
It was not possible to evaluate whether those with recent onset TD responded differently to those with more established problems, since no trial reported data for groups with different durations of TD that could be extracted for separate analyses.

1.5 Heterogeneity
Data were homogeneous. We did not detect clinical, methodological or statistical heterogeneity as described in Assessment of heterogeneity.

1.6 Sensitivity analyses
1.6.1 Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. Only one study was included for the primary outcome: consequently this sensitivity analysis could not be performed.

1.6.2 Assumptions for lost binary data
The above results are based on data as presented in the original study reports, with the assumption that those who left early before the end of the trial had not improved (see Dealing with missing data). We planned to test the sensitivity of the results to this assumption, but all randomised participants were reported for the primary outcome ‘no clinically important improvement in TD symptoms’. Therefore, we could not undertake this sensitivity analysis. If there had been a substantial difference, we would have reported results and discussed them but continued to employ our assumption.

1.6.3 Risk of bias
We planned to exclude trials that we judged to be at high risk of bias across one or more of the domains, but only one study was included for the primary outcome. Consequently this sensitivity analysis could not be performed.

1.6.4 Imputed values
We would have undertaken a sensitivity analysis to assess the effects of including data from cluster randomised trials where we used imputed values for ICC in calculating the design effect. No cluster randomised trials were included.

1.6.5 Fixed and random effects
We also synthesised data using a random effects model. This did not alter the effect estimates or CIs (analysis not shown).

2. Comparison 2: noradrenergic drugs versus dopaminergic drugs
2.1 TD symptoms
2.1.1 Not improved to a clinically important extent
The overall results for ‘clinically relevant improvement’ found no significant benefit of alpha-methylaspartate over placebo after 2 weeks’ treatment (1 trial, 20 people; RR 0.60, 95% CI 0.19 to 1.86; Analysis 2.1).

2.1.2 Not any improvement
We could not estimate the effect of alpha-methylaspartate compared with reserpine on any improvement in TD symptoms as no events were reported (1 trial, 20 participants, Analysis 2.2).

2.1.3 Deterioration of symptoms
We could not estimate the effect of alpha-methylaspartate compared with reserpine on deterioration of TD symptoms as no events were reported (1 trial, 20 participants, Analysis 2.3).

2.2 Heterogeneity, subgroup- and sensitivity analyses
Only one study was included in this comparison: consequently subgroup and sensitivity analyses could not be undertaken and there was no heterogeneity.

3. Comparison 3: dopaminergic drugs versus placebo
3.1 TD symptoms
3.1.1 Not improved to a clinically important extent
The overall results for ‘clinically relevant improvement’ found a significant benefit of reserpine over placebo after 2 weeks’ treatment (low-quality evidence, 1 trial, 20 people; RR 0.52, 95% CI 0.29 to 0.96; Analysis 3.1).

3.1.2 Not any improvement
For the outcome of ‘any improvement in TD symptoms’ we found no significant difference between dopaminergic drugs (Carbidopa/levodopa, L-dopa, reserpine) and placebo after 2 to 6 weeks’ treatment (3 trials, 57 people; RR 0.60, 95% CI 0.35 to 1.03; $I^2 = 0\%$, Analysis 3.2).

3.1.3 Deterioration of symptoms
There was no significant difference in deterioration of symptoms between people allocated to dopaminergic drugs (carbidopa/levodopa, reserpine) or placebo after 2 to 6 weeks’ treatment (very low quality evidence, 2 trials, 37 people; RR 1.18, 95% CI 0.35 to 3.99; $I^2 = 0\%$, Analysis 3.3).
3.2 Mental state

There was no significant difference between oxypertine and placebo on deterioration of mental state after 24 weeks' treatment (very low quality evidence, 1 trial, 42 people; RR 2.20, 95% CI 0.22 to 22.45; Analysis 3.4).

3.3 Leaving the study early

Using dopaminergic drugs (amantadine, bromocriptine, carbidopa/levodopa, oxypertine, tiapride) did not significantly affect the chances of a person leaving the study early compared with placebo after 2 to 24 weeks' treatment (very low quality evidence, 6 trials, 163 people; RR 1.29, 95% CI 0.65 to 2.54; \( I^2 = 58\% \), Analysis 3.5).

3.4 Subgroup analysis

3.4.1 Type of compound

There were no significant subgroup differences (\( I^2 = 0\% \), \( P = 0.90 \), Analysis 3.2) for reserpine versus placebo (RR 0.33, 95% CI 0.02 to 7.32; 20 participants, 1 study) and carbidopa/levodopa versus placebo (RR 0.95, 95% CI 0.26 to 3.6; 17 participants, 1 study) (see '3.5 Heterogeneity' below).

3.4.2 Duration of follow-up

Any effects that dopaminergic drugs may have did not clearly change in relation to duration of follow-up compared with placebo.

3.4.3 Clinical stage: recent onset TD

It was not possible to evaluate whether those with recent onset TD responded differently to those with more established problems, since no trial reported data for groups with different durations of TD that could be extracted for separate analyses.

3.5 Heterogeneity

Data were mostly homogeneous. We detected statistical heterogeneity (\( I^2 = 58\% \), \( P = 0.12 \)) as described in Assessment of heterogeneity for the outcome 'acceptability of treatment: leaving the study early'. Six studies reported on this outcome, but only two reported any events. One of these two studies reported an effect estimate favouring placebo over oxypertine after 24 weeks' treatment and the other study reported an effect estimate favouring carbidopa/levodopa over placebo after 6 weeks' treatment, but none of the studies reported statistically significant differences between groups (see Analysis 3.5 and '3.4.1 Type of compound' above).

3.6 Sensitivity analysis

3.6.1 Implication of randomisation

We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. Only one study was included for the primary outcome: consequently this sensitivity analysis could not be performed.

3.6.2 Assumptions for lost binary data

The above results are based on data as presented in the original study reports, with the assumption that those who left early before the end of the trial had not improved (see Dealing with missing data). We planned to test the sensitivity of the results to this assumption, but all randomised participants were reported for the primary outcome 'no clinically important improvement in TD symptoms'. Therefore we could not undertake this sensitivity analysis. If there had been a substantial difference, we would have reported results and discussed them but continued to employ our assumption.

3.6.3 Risk of bias

We planned to exclude trials that we judged to be at high risk of bias across one or more of the domains, but only one study was included for the primary outcome. Consequently this sensitivity analysis could not be performed.

3.6.4 Imputed values

We would have undertaken a sensitivity analysis to assess the effects of including data from cluster randomised trials where we used imputed values for ICC in calculating the design effect. No cluster randomised trials were included.

3.6.5 Fixed and random effects

We also synthesised data using a random-effects model. This did not alter the effect estimate or CIs for the primary outcome (analyses not shown).

4. Comparison 4: dopaminergic drugs versus other drugs

4.1 TD symptoms

4.1.1 Not improved to a clinically important extent

We found no significant benefit of tetrabenazine over haloperidol for 'no clinically relevant improvement after 18 weeks' treatment' (1 trial, 13 people; RR 0.93, 95% CI 0.45 to 1.95; Analysis 4.1).

4.1.2 Not any improvement

For the outcome of 'any improvement in TD symptoms', we found no significant difference between tetrabenazine and haloperidol after 18 weeks' treatment (1 trial, 13 people; RR 0.39, 95% CI 0.05 to 2.83; Analysis 4.2).

4.1.3 Deterioration of symptoms

There was no significant difference in deterioration of TD symptoms between people allocated to tetrabenazine or haloperidol after 18 weeks' treatment (1 trial, 13 people; RR 0.57, 95% CI 0.17 to 1.87; Analysis 4.3).

4.2 Leaving the study early

There was no significant difference between tetrabenazine and haloperidol in the chances of a person leaving the study early after...
3.2 Acceptability of treatment

It is always unclear what leaving the study early means. It could be to do with the participant not accepting treatment for a series of reasons, or of participants finding the trial intolerable. It also could be a function of a trial design in which willing participants are still asked to leave because of some degree of protocol violation. In any event, one study reported that 2/17 participants left the celiprolol group compared with a ‘not significantly different’ 0/18 in the placebo group.

3.3 Social confidence, social inclusion, social networks, or personalised quality of life

This group of outcomes was selected as being of importance to patients for the 2017 review update following a service user consultation. One study reported on ‘no improvement in quality of life’ and found no difference between celiprolol and placebo; however, we are uncertain about the results as the evidence is of very low quality.

4.3 Heterogeneity, and subgroup and sensitivity analyses

Only one study was included in this comparison. Consequently, subgroup and sensitivity analyses could not be undertaken; and there was no heterogeneity.

DISCUSSION

Summary of main results

1. The search

This area of research does not seem to be active. The 2017 update has identified additional data, but most trials predate the year 2000: only one was carried out after, published in 2010. This could be because of reasons such as less concern with TD, or less emergence of the problem in research-active communities because of more thoughtful use of antipsychotic drugs or loss of faith in non-antipsychotic catecholaminergic drugs as a potential treatment.

2. Few data

Only a little over 250 people have been included in this review. It is possible that real, and important, effects have not been highlighted because of the necessarily wide CIs of the findings. Many outcomes were not measured at all (see Overall completeness and applicability of evidence), including one of our pre-stated outcome measures. We may have been overambitious in hoping for some of these outcomes in TD trials but simple reporting of satisfaction with care or quality of life still does not seem too demanding and does remain of interest.

3. Comparison 1: noradrenergic drugs versus placebo

3.1 TD symptoms

Results from one study show that significantly more participants on alpha-methyl dopa than on placebo improved to a clinically important level at short term; however, our confidence in the evidence is low so further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

3.2 Acceptability of treatment

We are uncertain about the results on ‘deterioration in mental state’; evidence was of very low quality.

3.3 Acceptability of treatment

We are uncertain about the results on ‘acceptability of treatment’ measured by the number of participants leaving the study early; evidence was of very low quality.

No studies were identified that reported on adverse events or mental state, acceptability of treatment or social confidence, social inclusion, social networks, or personalised quality of life. See Summary of findings 3 for a summary of the evidence.

4. Comparison 2: noradrenergic drugs versus dopaminergic drugs

4.1 TD symptoms

Only one small, short duration trial reported on this comparison and found no difference between alpha-methyl dopa and reserpine on ‘no clinically important improvement in TD’. The size and duration of the trial were so limited that only a treatment of very great potency could have really shown up as effective.

No studies were identified that reported on adverse events, mental state, acceptability of treatment or social confidence, social inclusion, social networks, or personalised quality of life.

5. Comparison 3: dopaminergic drugs versus placebo

3.1 TD symptoms

Results from one small study show that significantly more participants on reserpine than on placebo improved to a clinically important level at short term; however, our confidence in the evidence is low so further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. We are uncertain about the results on ‘not any improvement in TD’ and ‘deterioration of TD’; evidence was of very low quality.

3.2 Mental state

We are uncertain about the results on ‘deterioration in mental state’; evidence was of very low quality.

6. Comparison 4: dopaminergic drugs versus other drugs

3.1 TD symptoms

Only one small, short duration trial reported on this comparison and found no difference between tetrabenazine and haloperidol on ‘no clinically important improvement in TD’, on ‘not any improvement in TD’, or on ‘deterioration of TD’. The size and duration of the trial were so limited that only a treatment of very great potency could have really shown up as effective.

3.2 Acceptability of treatment

None out of six participants left the tetrabenazine group compared with a ‘not significantly different’ two out of seven in the haloperidol group.

No studies comparing noradrenergic drugs versus placebo were identified that reported on adverse events or mental state. See Summary of findings for the main comparison for a summary of the evidence.
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia (Review)

2. Very small sample sizes resulting in downgrading evidence from the estimate of the effect.

Quality of the evidence

Overall, the quality of the evidence is low to very low. This means that we have limited to very little confidence in the effect estimates, and the true effect may be, or is likely to be, substantially different from the estimate of the effect. The main reasons for our low confidence in the evidence were as follows.

1. Poor study methodology and reporting of methods resulting in downgrading evidence for risk of bias. Overall the quality of reporting of these trials was poor (see Figure 3). Allocation concealment was not described; generation of the sequence was not explicit; studies were not clearly blinded and we are unsure if data are incomplete or selectively reported or if other biases were operating.

2. Very small sample sizes resulting in downgrading evidence for imprecision. The largest trial in this review randomised only 50 people. A trial of this size is unable to detect subtle, yet important, differences due to an intervention with any confidence. In order to detect a 20% difference between groups, probably about 150 people are needed in each arm of the study (alpha 0.05, beta 0.8).

3. Wide CIs (often due to low event rates) that included appreciable benefit or harm for the intervention as well as no effect, resulting in downgrading evidence for imprecision.

Potential biases in the review process

1. Missing studies

We made every effort to identify relevant trials. However, these studies are all small and it is likely that we have failed to identify other studies of limited power. It is likely that such studies would also not be in favour of the intervention group: if they had been so, it is more likely that they would have been published in accessible literature. We do not, however, think it likely that we have failed to identify large relevant studies.

2. Introducing bias

We have tried to be balanced in our appraisal of the evidence but could have inadvertently introduced bias. We welcome comments or criticisms. New methods and innovations now make it possible to report data where, in the past, we could not report data at all or had to report data in a different way. We think the 'Summary of findings' tables to be a valuable innovation — but problematic to those not ‘blind’ to the outcome data. It is possible to ‘cherry pick’ significant findings for presentation in this table. We have tried to decrease the chance of doing this by asking a new reviewer (HB) to select outcomes relevant for this table before becoming familiar with the data.

Agreements and disagreements with other studies or reviews

The only other relevant quantitative review we know of is the previous Cochrane Review (El-Sayeh 2006). This update expands and improves this review but does not substantially change the conclusions.

AUTHORS’ CONCLUSIONS

Implications for practice

1. For people with antipsychotic-induced tardive dyskinesia

These studies provide no useful information for service-users. It is unlikely that these data will impact upon the uptake of established strategies for TD such as early detection, dose/drug modification, vitamin E and use of tetrabenazine. However, people with TD could consider these as other experimental treatments for which very little supportive data exist. Few data exist for any treatment for TD.

2. For clinicians

These treatments are purely experimental. This does not mean that they are not viable choices. If the drugs are available, these...
treatments could be used, but it would be advisable to study use of these treatments within a real-world randomised trial.

3. For policy makers

There seem few implications for policy makers except that, perhaps, these compounds should only be used for TD within the context of a well-designed randomised controlled trial.

Implications for research

1. General

The power of this review would have been greatly enhanced by better reporting of data. For example, none of the studies made explicit how randomisation was undertaken; and few studies provide data for before the first period of cross-over. We realise that much of the work for these trials predates CONSORT — first published in Begg 1996 — and that it is only too easy to judge studies of the past by standards of today. Future studies, however, should report to a much higher standard than what we have seen in trials eligible for this review.

2. Specific

Well-designed randomised controlled trials, involving a large number of participants over protracted periods of time, are needed if we are to see if non-antipsychotic catecholaminergic drugs could have a role in prevention and treatment of TD. Such studies are of importance to people with the problem, who have long been ignored (Figure 1).

2.1 Use of cross-over design

Despite a large number of studies initially highlighted in the search, the data available for this review are very limited. The large number of studies we found, together with the disparate nature of these compounds, highlights the effort as well as the frustration that has gone into researching this topic. As previously mentioned, it is difficult to draw conclusions from a study that only includes 12 participants (Buruma 1982). It seems wasteful that so many studies were excluded because of inadequately designed cross-over formats. Although there are certain advantages in using a cross-over design in chronic conditions such as TD, there are also major disadvantages, one of which is the expected duration over which the drugs in question exert their actions. This cannot be considered as consisting solely of the time taken for the active drug to be removed from the bloodstream — the much longer period of time that these drugs may effect neurotransmitter or receptor function as well as structure must also be considered. It cannot be assumed that a washout period of a few weeks or less will adequately counteract these carry-over effects. TD is also an unstable condition and people with TD may not remain compliant with medication. All these factors make the arguments for not using cross-over methodology strong, despite the initial attraction (Armitage 1991; Fleiss 1984; Pocock 1983).

2.2 Sample size

The results suggest that larger sample size should be used to provide more precise estimates of effect and to help avoid false conclusions about the effects of the proposed treatment.

2.3 Length of study

Only one study included in this review used the intervention for more than five months (Soni 1986). TD, however, is a chronic condition of insidious onset, the severity of which fluctuates spontaneously (APA 1992). Even if the compounds under investigation have a swift effect, it is the long-term outcomes that must be considered of most clinical value.

2.4 Outcomes

Scale-derived data do have their place. It is important that a scale is validated for measuring changes secondary to treatment in those with TD. Many studies have not used clinically meaningful markers of outcome. They instead tend to either use obscure/modified ratings scales (such as SKAUB) (Hebenstreit 1986); or even more nebulous surrogate end-point measures. Scale-derived data do have their place, but it is important that a scale is validated for measuring changes secondary to treatment in those with TD. In addition, many of the outcomes we initially desired when we started this review have not been investigated. Finally, a service user consultation also informed the addition of outcomes of special importance to patients. We have reconsidered all these outcomes in case they were too ambitious and tried to tailor them to a real-world pragmatic trial design (see Table 2). Future studies could be well served by using guidelines as described in the CONSORT statement (Moher 2001). These may help avoid some of the rectifiable flaws in the study methodologies and as a result allow more studies to be included in the final analyses.

Acknowledgements

We would like to thank Clive Adams, Gill Rizzello and Tessa Grant for their advice and technical support. Thanks also to Ben Gray for writing the Plain Language Summary, and to Farhad Sokraneh for carrying out the 2015 trial search. We would like to thank João Paulo Lyra da Silva for his contribution to the previously published version of this review. We are also grateful to Dawn-Marie Walker, Ruth Sayers, Megan Lees, and Vanessa Pinfold from McPin Foundation for organising and holding the public- and patient-involvement consultation with TD service users that contributed to selecting outcomes for the ‘Summary of findings’ tables and to guiding future research. Finally, we wish to thank Rosie Asher and Antonio Grande for screening literature and helping with data extraction for the 2017 update, and Nicholas Henschke, Linda Levi and Loukia Spineli for assisting with updating the report.
References to studies included in this review

Buruma 1982 (published data only)


Chen 1995 (published data only)

Hebenstreit 1986 (published data only)

Huang 1981 (published data only)

Karniol 1983 (published data only)

Kazamatsuri 1973 (published data only)

Pappa 2010 (published data only)

Rust 1984 (published data only)

Simpson 1988 (published data only)

Soni 1986 (published data only)

References to studies excluded from this review

Adler 1990 (published data only)

Alpert 1983 (published data only)

Angrist 1997 (published data only)

Asher 1981 (published data only)

Auberg er 1985 (published data only)

Bateman 1979 (published data only)

Braun 1989 (published data only)

Browne 1986a (published data only)

Chien 1978 (published data only)

Chouza 1980 (published data only)

Delwaide 1979 (published data only)

Delwaide 1980 (published data only)

Diehl 1999 (published data only)


DiMascio 1976 (published data only)


Doongaji 1982 (published data only)

Fahn 1983 (published data only)

Fann 1976 (published data only)

Ferrari 1972 (published data only)

Freeman 1980 (published data only)

Gardos 1979 (published data only)

Gerlach 1976 (published data only)


Glover 1980 (published data only)

Godwin Austen 1971 (published data only)

Goff 1993 (published data only)
Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo DA. A placebo-controlled trial of selegiline (L-deprenyl)

Greendyke 1988 (published data only)

Gutierrez 1979 (published data only)

Hemnani 1982 (published data only)

Jankovic 1982 (published data only)

Jeste 1983 (published data only)

Kazamatsuri 1972 (published data only)

König 1996 (published data only)

Leblhuber 1987 (published data only)

Levy 1984 (published data only)

Lieberman 1988 (published data only)

Lieberman 1989 (published data only)

Ludatscher 1989 (published data only)

Nasrallah 1986 (published data only)

NCT00310661 2006 (published data only)

NCT00845000 2009 (published data only)

O'Suilleabhain 2003 (published data only)

Reker 1982 (published data only)

Ringwald 1978 (published data only)

Rondot 1987 (published data only)

Silver 1995 (published data only)
* Silver H, Geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine on Parkinsonian- and...


Smith 1977 *(published data only)*

Stearns 1996 *(published data only)*

Tamminga 1980 *(published data only)*

Viu kari 1975 *(published data only)*

Additional references

Alabed 2011

Altm an 1996

APA 1992

Armitage 1991

Ascher-Svanum 2008

Ballesteros 2000

Barnes 1993

Begg 1996

Bergen 1989

Bergman 2017

Bhoopathi 2006

Bland 1997

Boissel 1999

Browne 1986b

Cadet 1989
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia (Review)

Elbourne 2002

Essali 2011

Fernandez 2001

Fleiss 1984

Friedhoff 1977

Furukawa 2006

Glazer 1990

Glazer 2000

Gullifford 1999

Guy 1970

Guy 1976

Higgins 2003

Casey 1994

Cavallaro 1993

Chouinard 2008

Cloud 2014

Correll 2004

Correll 2008

Deeks 2000

Divine 1992

Donner 2002

Egger 1997

Elbourne 2002
Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthington HV, Vaile A. Meta-analyses involving cross-
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia (Review)

Higgins 2011

Jadad 1996

Jeste 1988

Jeste 2000

Jüni 2001

Kane 1982

Kay 1986

Leon 2006

Leucht 2005a

Leucht 2005b

Lieberman 1996

Maher 2012

Marshall 2000

Martins 2011

Moher 2001

NICE 2014
NICE. Psychosis and schizophrenia in adults: treatment and management. NICE clinical guideline 178 (guidance.nice.org.uk/cg178) 2014.

Overall 1962

Pocock 1983

Sachdev 2000

Schooler 1993

Schulz 1995

Schünemann 2011

Smith 1980

Soares-Weiser 1997
Soares-Weiser K, Mobsy C, Holliday E. Anticholinergic medication for neuroleptic-induced tardive dyskinesia.
Cochrane Database of Systematic Reviews 1997, Issue 2. [DOI: 10.1002/14651858.CD000204]

Soares-Weiser 2003

Soares-Weiser 2006
Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD000458.pub2]

Soares-Weiser 2011

Tarsy 2011

Taylor 2009

Characteristics of included studies [ordered by study ID]

Buruma 1982

Methods
Allocation: randomised, no further details.
Blindness: unclear.
Duration: 4 weeks (2 weeks then crossed over to another 2 weeks).
Design: cross-over.
Setting: inpatients at 2 long-stay psychiatric hospitals, the Netherlands.
Raters: blinding of raters not reported.

Participants
Diagnosis: psychiatric disease (no operational criteria) and institutionalised with antipsychotic-induced tardive dyskinesia.
N = 12.
Sex: 4 M, 8 F.
Age: range 39 to 70 years, mean 59 years.
Duration of TD: not reported.

Interventions
1. Tiapride: dose 100 mg tid/day for 2 weeks. N = 7.

El-Sayeh 2006

* Indicates the major publication for the study

References to other published versions of this review

El-Sayeh 2006
Buruma 1982 (Continued)

Previous treatment, including that prescribed for the TD, was continued without alterations throughout the trial. No further details on concomitant medications were reported.

Outcomes
Leaving the study early.
Unable to use -
Adverse effects: tardive dyskinesia (doppler-radar movement counter, videotaped dyskinesia scores, not reported pre-cross-over).

Notes
Sponsorship source: Delagrange provided Tiapride. Additional sponsorship details not reported.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;Patients were randomly allocated to two groups&quot;; further details not reported.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Allocation concealment not reported.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Unclear, in the introduction it is stated that: &quot;However, the results from these studies seemed to justify a double-blind controlled cross-over trial and objective evaluation of the effect of Tiapride on the involuntary movements&quot;; the Methods section does not report blinding.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Blinding not reported.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;All twelve patients completed the trial&quot;.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>&quot;Besides these quantitative methods, self-assessment analogue three-point scales were made by the patients, and subjective analogue ratings were made on a five-point scale by family, nurses and attendant doctors. At each recording session the patient was asked about possible side-effects of the treatment. At each investigation motor performance speed was quantified (Schuhfried apparatus) to study possible parkinsonian effect of Tiapride &quot;. &quot;The results of the assessment analogue scales were inaccurate. The patients gave inconsistent answers in 3.1%, the nurses and the attendant doctors even in 37%. Further analysis of the subjective results has been discarded because of the reason outlined above and the fact that statistical analysis on three and five-point scales does not have enough sensitivity for such a small group of patients.&quot;</td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>&quot;the randomization has partly failed with respect to the seriousness of the dyskinesia of the patients: the second group consisted of more affected patients.&quot;</td>
</tr>
</tbody>
</table>

Chen 1995

Methods
Allocation: "cross over randomized trial".
Blinding: double-blind with adequate description.
Duration: 4 weeks.

Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia (Review)
Chen 1995 (Continued)

Design: cross-over.
Setting: inpatients, China.
Raters: blinding of raters not reported.

Participants
Diagnosis: Antipsychotics-induced tardive dyskinesia.
N = 20*.
Sex: 12 M, 8 F.
Age mean 34.86 (SD 7.82) years old.
Duration of TD: mean 3.52 (SD 2.38) years.

Interventions
1. Bromocriptine Group: at first phase of the trial, the participants received bromocriptine, 1 capsule each time, twice per day for 4 weeks. The second phase was a 2-week washout period. At the third phase of the trial, the participants received placebo for 4 weeks. N = 10.*
2. Placebo Group: at first phase of the trial, the participants received placebo for 4 weeks. The second phase was a 2-week washout period. At the third phase of the trial, the participants received bromocriptine, 1 capsule each time, twice per day for 4 weeks. N = 10.*
All participants received stable doses of antipsychotics before and during the study. Other concomitant medication was not reported.

Outcomes
Leaving the study early.
Unable to use (data from first phase before cross-over not reported separately) -
Abnormal Involuntary Movement Scale (AIMS).
Clinical response of TD:**
Adverse events: dizziness, nausea.

Study authors were contacted but no more information was received.

Notes
*sequential test method was used; when the 10th participants completed the trial, a significant difference was detected, so they terminated enrolling participants.
**clinical improvement defined as the decrease rate of AIMS score ≥ 20%.
Data extracted by Sai Zhao from Chinese language report.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;cross over randomized trial&quot;; no further details reported.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>&quot;the interventions were coded as intervention A or B by the researcher in pharmacy&quot;</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>&quot;double blind study, the interventions were coded as intervention A or B by the researcher in pharmacy&quot; &quot;Participants and personnel did not know the allocation result&quot;. The 2 drugs were contained in capsules with same appearance. Blinding of participants and key study personnel ensured.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not reported.</td>
</tr>
</tbody>
</table>
### Chen 1995 (Continued)

#### All outcomes

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data</td>
<td>Low risk</td>
<td>All participants completed the study.</td>
</tr>
<tr>
<td>(attrition bias)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Unclear if all predefined outcomes have been reported. A protocol is not available for verification.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>The study seems to be free of other sources of bias.</td>
</tr>
</tbody>
</table>

#### Hebenstreit 1986

**Methods**

- Allocation: randomised, no further details.
- Blindness: double (identical film-coated tablets).
- Duration: 3 months.
- Design: parallel.
- Setting: psychiatric ward, Austria.
- Raters: all assessments were made by the same examiner. No reference to rater blinding was reported.

**Participants**

- Diagnosis: symptoms of TD using AIMS.
- N = 35.
- Sex: only female.
- Age: range 43 to 82 years.
- Duration TD: not reported.

**Interventions**


All patients received additional antipsychotic medication.

**Outcomes**

- Improvement in TD symptom using SKAUB (German version of AIMS).
- Quality of life.
- Leaving the study early.
- Unable to use - Adverse effects: diarrhoea, hypotensive circulatory dysregulation, collapsing, cold sensation in extremities, tremor, heartburn, dizziness, sleeplessness, changes in blood pressure (systolic and diastolic) and pulse (no usable data).

**Notes**

- No information on sponsorship.
- Article in German.

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;randomized&quot;; details not reported.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Allocation concealment not reported.</td>
</tr>
</tbody>
</table>

Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia (Review)
### Hebenstreit 1986 (Continued)

<table>
<thead>
<tr>
<th>Blinding of participants and personnel (performance bias)</th>
<th>Low risk</th>
<th>Double blind, identical film-coated tablets.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>No information is provided.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Exclusions are reported but no information on whether they were accounted for or discounted from the analysis.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>Outcome data for adverse events not fully reported.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>The study seems to be free from other sources of bias.</td>
</tr>
</tbody>
</table>

### Huang 1981

**Methods**
- Allocation: randomised.
- Blindness: double blind, identical-appearing capsules.
- Duration: each patient was observed for 4 days in a control period before test medication was given. This was followed by a period of 2 weeks of research medication, and a post-medication period.
- Design: parallel.
- Setting: inpatients, USA.
- Raters: assessments were done subjectively by the same observer at the same time (4:00pm) every day.

**Participants**
- Diagnosis: psychosis (diagnosis details not reported); antipsychotic induced TD.
- Total number randomised: N = 30.
- Sex: not reported.
- Age: 40 to 65 years.
- Duration of TD: no information.

**Interventions**
1. Alpha-methylldopa (Aldomet)*: 750 to 1500 mg/d. N = 10.
2. Reserpine*: 0.75 to 1.5 mg/d; N = 10.

Patients were allowed to continue taking antipsychotic and anticholinergic medications throughout this study as required to control persistent psychosis. Antipsychotic and antiparkinsonism medications had been stabilized for more than 1 year and were kept strictly constant.

**Outcomes**
- TD symptoms: improvement and deterioration.
- Unable to use.
- TD symptoms scale scores, using a tardive dyskinesia rating scale with no published psychometric tests.
### Huang 1981 (Continued)

Adverse effects: sedation, hypotension and mood depression (no usable data).

**Notes**

Sponsorship source: not reported.

*The dose of the research medication was increased during the testing period in order to obtain maximal therapeutic response.*

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>“Thirty patients were randomly assigned to three medication groups”; no further details reported.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Allocation concealment not reported.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>“The study was carried out by a double-blind controlled method. Each identical appearing capsule contained either a-methyldopa (Aldomet) 250 mg, reserpine 0.25 mg or placebo (lactose)”.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>“The severity of... movements were assessed subjectively by the same observer (C. C. Huang) at the same time (4:00pm) every day”, but blinding details of outcome assessor were not reported.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>All subjects seem to have completed the 2-week study. However, attrition information has not been clearly reported.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias) All outcomes</td>
<td>High risk</td>
<td>Adverse effects data not reported. Efficacy data reported as ‘medication scores’: “The mean of daily scores recorded during the 7 days in which the highest doses were given was designated as the medication score.” Post medication scores reported for 22/30 subjects: “Post-medication evaluations were followed in eight patients who received alpha-methyldopa, nine patients who received placebo and in five patients who received reserpine.”</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Baseline information available only for the premedication scores per group (groups are balanced).</td>
</tr>
</tbody>
</table>

### Karniol 1983

**Methods**

Allocation: "randomly" - the drugs were given in sealed opaque envelope.
Blindness: double, described.
Design: parallel group.
Duration: 5 weeks.
Setting: inpatients, Brazil.
Rater: not described.

**Participants**

Diagnosis: 15 participants with schizophrenia, 2 with other associated psychosis, and 2 with effective psychosis and 1 mental retardation.
N = 20.
Sex: 10 M, 10 F.
Age: 58.2 years.
Interventions

2. L-dopa 500 mg: growing dosage per week. From the fourth week the dosage was 500 mg. N = 5.
3. L-dopa 1000 mg: growing dosage per week. From the fourth week the dosage was 1000 mg. N = 5.
4. L-dopa 2000 mg: growing dosage per week. From the fourth week the dosage was 2000 mg. N = 5.

All participants were on antipsychotics for a period higher than 6 months, 17 participants were on antipsychotic at the study period, 9 participants were on anticholinergic and 8 had hypnotic or anticonvulsants.

Outcomes

TD symptoms: any improvement.
Unable to use -
TD symptoms: Bordeleau scale/EBS (only medians reported).

Notes

Sponsorship source: not reported.
Article in Portuguese; assessed and data extracted by Antonio Grande.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;participants were randomly assigned to each group&quot;.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>&quot;the drugs were given in sealed opaque envelope&quot;.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>Each week a number of envelopes were given to the nurse containing a number, so only the researcher knew what was being administered.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not enough information in the study.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>No mention about loss of follow-up.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>Author reported only TD score medians and there is no availability of study protocol.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>The study seems to be free of other sources of bias.</td>
</tr>
</tbody>
</table>

Kazamatsuri 1973

Methods

Allocation: "randomly".
Blindness: double.
Duration: 18 weeks.
Design: parallel.
Setting: Inpatients, USA.
**Participants**

Diagnosis: chronic psychotic patients who manifested typical bucco-linguo-masticatory oral dyskinesia associated with long-term antipsychotic medication.  

N = 13.  

Sex: 8 M, 5 F.  

Age: mean 55.8 years, range 41 to 63 years.  

Duration of TD: no information available.

**Interventions**

1. Haloperidol: dose 4 mg b.i.d. From week 15 dose was doubled to 16 mg/d. N = 7.  
2. Tetrabenazine: dose 50 mg b.i.d. From week 15 onwards, dose was doubled to 200 mg/d. N = 6.  

Pre-placebo period: initially, all antipsychotic and antiparkinsonian drugs were completely withdrawn and were replaced by placebo for the first 4 weeks.  

Other medications, such as antidiabetic or anticonvulsant drugs were continued unchanged.

**Outcomes**

TD symptoms: not improved.  
TD symptoms: deterioration.  
Leaving the study early.

**Notes**

Sponsorship source: supported in part by Public Health Service grant from the National institute of Mental Health. Tetrabenazine and placebo tablets were provided by Hoffman-La Roche.

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;The 13 patients were divided randomly into two groups&quot;; further details not reported.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Allocation concealment not reported.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>Blinding of participants and personnel not reported.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>&quot;A frequency count of mouth movements, done by a psychiatrist blind to the study design, was used to assess oral dyskinesia&quot;.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>2/7 (29%) subjects dropped out from the haloperidol group during the 18th week; no further details are provided for addressing the outcomes of these participants. No participants dropped out from the tetrabenazine group.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Unclear if all predefined outcomes have been reported.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Insufficient information to make a judgement.</td>
</tr>
</tbody>
</table>
Methods
Allocation: "randomly assigned".
Blindness: double, identically appearing capsules.
Duration: 4 weeks and 4 days (2 weeks followed by 4 days wash-out then another 2 weeks).
Design: cross-over.
Setting: outpatients, Greece.
Raters: "Tardive dyskinesia was assessed by means of the Abnormal Involuntary Movements Scale (AIMS) by a blinded, experienced rater".

Participants
Diagnosis: schizophrenia and TD (DSM-4) and stable psychiatric condition.
N = 22.
Sex: 14 M, 8 F.
Age: mean 52 years, range 32 to 68 years.
Duration of TD: patients have been ill for 10 (SD 7) years and were receiving stable medical treatment.

Interventions
1. Amantadine: dose 100 mg/d for 2 weeks (followed by 4-day washout and 2 weeks of placebo). N = 11.
2. Placebo: 2 weeks (followed by 4-day washout and 2 weeks of amantadine). N = 11.
Patients received their usual antipsychotic treatment at the same dosage.

Outcomes
Leaving the study early.
Unable to use -
changes in TD severity at baseline and endpoint using AIMS.
Mental state: BPRS, MMSE, CGI.
Adverse effects: insomnia, constipation, dizziness, headache.
Study authors were contacted for additional data, no information was received.

Notes
Sponsorship source: there was no financial funding for this study.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;Eligible patients were randomly assigned to receive either amantadine or placebo&quot;; further details not reported.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Allocation concealment not reported.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>&quot;Participants received identically appearing capsules containing either amantadine (100 mg) or placebo.&quot; &quot;double blind&quot;; however the authors report that &quot;Those unable to safely tolerate each succeeding dose returned to a lower dose for the remainder of the study or until they were able to tolerate a higher dose&quot;. This may have unblinded personnel.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>&quot;Tardive dyskinesia was assessed by means of the Abnormal Involuntary Movements Scale (AIMS) by a blinded, experienced rater&quot;. &quot;All safety issues were handled by an unmasked safety officer who was not involved in data collection&quot;.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>&quot;All 22 enrolled patients completed the study&quot;.</td>
</tr>
</tbody>
</table>
Pappa 2010 (Continued)

Selective reporting (reporting bias) | High risk | Many outcomes were not fully reported. TD outcomes: average scores (no SD), range and P for amantadine and placebo at baseline and end of the study have been reported. Mental state outcomes (BPRS, MMSE, CGI): average scores (no SD), range and P for amantadine and placebo reported only for end of study.

Other bias | Unclear risk | Insufficient information to make a judgement.

Rust 1984

Methods

Allocation: "random".
Blindness: double.
Duration: 8 weeks.
Design: parallel.
Setting: inpatients, France.
Raters: not reported.

Participants

Diagnosis: schizophrenia (25), organic or affective psychoses, severe personality disorders + dyskinesia (mainly localized to the buccofacial region) induced by long-term antipsychotic treatment.
N = 50.
Sex: 50 M.
Age: mean 48 years.
Duration of TD: in both groups the dyskinesia had been present for an average period of 4 years.

Interventions

1. Tiapride: dose 400 mg/d for the first 30 days followed by 600 mg/d for the next 30 days. N = 25.
Throughout the course of the study the patients continued to take antipsychotics to avoid spontaneous remission or worsening of symptoms. Other associated medication such as anticholinergic drugs was not prescribed during the study. Patients had not been treated previously for their dyskinesia.

Outcomes

Leaving the study early.
Unable to use -
TD symptoms: Skaub's scale (German version of AIMS) - reduction of symptoms.

Notes

Sponsorship source: not reported.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;random allocation of either tiapride or placebo for 8 weeks&quot;; further details not reported.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Allocation concealment not reported.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>&quot;double-blind&quot;. Details not reported.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>&quot;double-blind&quot;. Details not reported.</td>
</tr>
</tbody>
</table>
Rust 1984 (Continued)

Incomplete outcome data (attrition bias) All outcomes
- Low risk
  "all patients continued in the study until the end of treatment."

Selective reporting (reporting bias)
- Unclear risk
  Unclear if all predefined outcomes have been reported. Reduction of symptoms not fully reported.

Other bias
- Unclear risk
  Insufficient information to make a judgement. Baseline characteristic not reported per intervention group. Unclear if there were confounding variables.

Simpson 1988

Methods
- Allocation: "randomly assigned".
- Blindness: double, identical-appearing tablets.
- Duration: 20 weeks (6 weeks observation, 4 weeks dose finding, 6 weeks' treatment, 4 weeks follow-up).
- Design: parallel.
- Setting: Inpatients from 2 chronic care institutions, USA.
- Raters: not reported.

Participants
- Diagnosis: tardive dyskinesia in subjects treated with antipsychotics.
  - N = 17.
  - Sex: 8 M, 9 F.
  - Age: mean 46 years, range 32 to 70 years.
- Duration of TD: no information.

Interventions
  "When the appropriate dose was established in the dose finding period, patients received that dose for the next 6 weeks".
- Concomitant medication: no information.

Outcomes
- TD symptoms: improvement and deterioration (AIMS and Simpson Abbreviated Dyskinesia Scale).
- Leaving the study early.
- Unable to use -
- Treatment-related side-effects.
- Mental state: BPRS, SANS (F and P values only).

Notes
- Sponsorship source: not reported. Medication and placebo supplied by Merck Sharp and Dohme, Rahway, NJ. (Unclear if medications were supplied free of charge).

Risk of bias

Bias
- Authors' judgement
  - Support for judgement
**Simpson 1988** (Continued)

<table>
<thead>
<tr>
<th>Method</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>&quot;Patients were randomly assigned&quot;; further details not reported.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Allocation concealment not reported.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>&quot;active (Sinemet) or placebo tablets (supplied by Merck Sharp and Dohme, Rahway, N.J). Both groups of patients received the same number of identical-appearing tablets.&quot;</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>&quot;double-blind&quot;. Details not reported.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>&quot;Fifteen of the 17 patients completed the trial; there were two dropouts. A female patient experienced &quot;seizures&quot; and the blind was, therefore, broken; a male patient eloped from the hospital. Both patients were found to be in the placebo group.&quot; 25% dropped out from the placebo group versus 0% in the active medication group. According to the degrees of freedom in the F-test, only completers must have been analysed.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>&quot;Because the AIMS and Simpson scale were very highly correlated, only data from the Simpson scale are presented.&quot; Also, mental state data (BPRS and SANS) unusable: reported as F and P values. Adverse Events (Treatment Emergent Side Effects Scale) outcome data not reported.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Insufficient information reported to make a judgement.</td>
</tr>
</tbody>
</table>

**Soni 1986**

<table>
<thead>
<tr>
<th>Method</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation:</td>
<td>&quot;randomly allocated&quot; unclear.</td>
</tr>
<tr>
<td>Blindness:</td>
<td>double, unclear.</td>
</tr>
<tr>
<td>Duration:</td>
<td>24 weeks.</td>
</tr>
<tr>
<td>Design:</td>
<td>parallel.</td>
</tr>
<tr>
<td>Setting:</td>
<td>Inpatients in a psychiatric hospital, UK.</td>
</tr>
<tr>
<td>Raters:</td>
<td>AIMS assessments were carried out by the same rater throughout the study and the rater was blind to the treatment.</td>
</tr>
<tr>
<td>Participants</td>
<td>Diagnosis: RDC criteria for chronic schizophrenia and associated TD. N = 42.</td>
</tr>
<tr>
<td></td>
<td>Sex: 25 M, 17 F.</td>
</tr>
<tr>
<td></td>
<td>Age: mean 59 years, range 42 to 71 years.</td>
</tr>
<tr>
<td></td>
<td>Duration of TD: TD present for at least 3 consecutive months.</td>
</tr>
<tr>
<td>Interventions</td>
<td>1. Oxypertine: flexible dose 80 mg/d to 240 mg/d for 24 weeks. N = 20.</td>
</tr>
<tr>
<td></td>
<td>&quot;It was required that their psychiatric condition had been stable on conventional neuroleptic medication for at least 12 months before entry.&quot;</td>
</tr>
<tr>
<td></td>
<td>Anticholinergic antiparkinsonian drugs already prescribed were maintained throughout the trial. The only other drug permitted was nitrazepam for insomnia (10 to 20 mg) but only when required.</td>
</tr>
</tbody>
</table>
Soni 1986 (Continued)

Outcomes

Mental state: clinical relapse of psychosis.
Leaving the study early.
Unable to use -
Adverse events: AIMS, EPS (not fully reported).

Notes

Sponsorship source: Sterling Winthrop Ltd.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>“randomly allocated to either the treatment or the control group”; further details not reported.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Allocation concealment not reported.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>“double-blind”, matched placebo. Details not reported.</td>
</tr>
</tbody>
</table>

Blinding of outcome assessment (detection bias) All outcomes

| Low risk | The AIMS assessment was carried out by the same rater throughout the study and the rater was blind to the treatment. |

Incomplete outcome data (attrition bias) All outcomes

| High risk | “11 oxypertine and 7 placebo patients has withdrawn...” High overall rate of participants dropping out (45%): oxypertine group (55%) and placebo group (32%). |

Selective reporting (reporting bias)

| High risk | “Table 2 gives the results of only those analyses which showed a statistically significant change: non-significant results are excluded." Global AIMS scores not reported. EPS data descriptively reported. |

Other bias

| Low risk | The study seems to have been free of other sources of bias. The 2 groups were well matched on specific baseline characteristics. |

General

Acn - anticholinergics
Bz - benzodiazepine
CPE - chlorpromazine equivalent
Scales
AIMS - Abnormal Involuntary Movement
BRS - Barnes & Kiddger Rating
GRS - Gerlach Rating
SEPS - Smith Extrapyramidal
SRS - Simpson Rating Scale

Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adler 1990</td>
<td>Allocation: randomised.</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
Participants: patients with tardive dyskinesia and at least 2-year exposure to antipsychotic drugs.  
Intervention: carbidopa/levodopa 30/300 mg vs carbidopa/levodopa 50/500 mg vs carbidopa/levodopa 75/750 mg. A non-randomised treatment as usual group was also included.  
Outcomes: not reported for the pre-defined randomised groups. 5 subjects were randomised to 3 groups. N per group and baseline characteristics not reported. Data reported for “low dose” and “high dose” participants based on what appears to be a post hoc decision, and not for each intervention group separately. Study authors were contacted for data: no information was received and this over 30 years old study was excluded. |
| Angus 1997 | Allocation: randomised.  
Participants: chronically ill psychiatric inpatients with TD.  
Interventions: amantadine vs placebo.  
Outcomes: no usable data, not reported for the first phase before crossing over.  
No up-to-date contact details were found for the study authors of this 19-year-old study. |
| Auberger 1985 | Allocation: double blind, cross-over.  
Participants: people with chronic tardive dyskinesia.  
Interventions: tiapride versus placebo.  
Outcomes: no usable data, not reported for the first phase before crossing over.  
No up-to-date contact details were found for the study authors of this over 30-year-old study. |
| Bateman 1979 | Allocation: randomised.  
Participants: people with schizophrenia and antipsychotic induced tardive dyskinesia.  
Intervention: placebo versus haloperidol versus metoclopramide.  
Outcomes: no usable data, not reported for the first phase before crossing over.  
No up-to-date contact details were found for the study authors of this over 35-year-old study. |
| Braun 1989 | Allocation: unclear; "double-blind crossover".  
Participants: Huntington’s disease (5), Tourette’s syndrome (2), tardive dyskinesia (2), idiopathic torsion dystonia (1).  
Intervention: SKF 38393 (selective D-1 dopamine receptor agonist) versus placebo.  
Outcomes: no usable data, not reported for the first phase before crossing over.  
We were unable to identify up-to-date study author contact details for this over 25-year-old study. |
| Browne 1986a | Allocation: randomised.  
Participants: adult outpatients suffering with antipsychotic-induced tardive dyskinesia.  
Intervention: sodium valproate versus oxypertine versus deanol versus placebo.  
Outcomes: no usable data, not reported for the first phase before crossing over. |
<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chien 1978</td>
<td>Allocation: randomised. Participants: people with TD. Intervention: sodium valproate versus oxypertine versus deanol. Outcomes: no usable data, not reported for the first phase before crossing over. We were unable to identify up-to-date study author contact details for this 30-year-old study.</td>
</tr>
<tr>
<td>Chouza 1982</td>
<td>Allocation: not randomised.</td>
</tr>
<tr>
<td>Delwaide 1979</td>
<td>Allocation: randomised. Participants: hospitalised patients with tardive dyskinesia on a psychogeriatric ward. Intervention: thiperazine versus tiapride versus placebo. Outcomes: no usable data, not reported for the first phase before crossing over. The study is over 35 years old and we were unable to identify contact details for the author.</td>
</tr>
<tr>
<td>Delwaide 1980</td>
<td>Allocation: not randomised. Participants: people with dementia and TD. Intervention: all participants were started on placebo and then switched to bromocriptine.</td>
</tr>
<tr>
<td>Diehl 1999</td>
<td>Allocation: randomised. Participants: tardive oro-facial dyskinesia. Intervention: pergolid 0,15 mg/d vs placebo. Outcomes: results not reported for the studied outcomes (irrespective of cross-over period). Study authors were contacted for data. No information was received and this over 15-year-old study was excluded.</td>
</tr>
<tr>
<td>Doongaji 1982</td>
<td>Allocation: randomised. Participants: diagnosis of TD. Interventions: metoclopramide vs placebo. Outcomes: no usable data, not reported for the first phase before crossing over. Study authors were contacted but no information was received. Consequently, this over 30-year-old study was excluded.</td>
</tr>
<tr>
<td>Fahn 1983</td>
<td>Allocation: not randomised.</td>
</tr>
<tr>
<td>Ferrari 1972</td>
<td>Allocation: not randomised.</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>--------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Gardos 1979</strong></td>
<td>Intervention: oxypertine versus placebo. Outcomes: no usable data, not reported for the first phase before crossing over. No up-to-date contact details were found for the study authors of this over 35 years old study.</td>
</tr>
<tr>
<td><strong>Gerlach 1976</strong></td>
<td>Allocation: not randomised, controlled clinical trial.</td>
</tr>
<tr>
<td><strong>Glover 1980</strong></td>
<td>Allocation: randomised. Participants: adult patients with significant antipsychotic-induced tardive dyskinesia. Intervention: amantadine versus placebo. Outcomes: no usable data, not reported for the first phase before crossing over. No up-to-date contact details were found for the study authors of this over 35 year-old-study.</td>
</tr>
<tr>
<td><strong>Godwin Austen 1971</strong></td>
<td>Allocation: randomised. Participants: people with moderate to severe dementia and antipsychotic induced tardive dyskinesia. Intervention: diazepam vs tetrabenazine. Outcomes: no usable data, not reported for the first phase before crossing over. Study is over 40 years old, we were unable to identify contact details for the authors.</td>
</tr>
<tr>
<td><strong>Goff 1993</strong></td>
<td>Allocation: randomised. Participants: antipsychotic-induced tardive dyskinesia according to DSM-III-R (SCID), Schooler and Kane criteria. Interventions: selegiline vs placebo. Included in Miscellaneous review.</td>
</tr>
<tr>
<td><strong>Greendyke 1988</strong></td>
<td>Allocation: randomised. Participants: psychiatric inpatients with TD. Interventions: pindolol versus placebo. Outcomes: no usable data reported in this brief report. No up-to-date contact details were found for the study authors of this over 25-year-old study.</td>
</tr>
<tr>
<td><strong>Gutierrez 1979</strong></td>
<td>Allocation: randomised. Participants: people with schizophrenia and extrapyramidal symptoms, not tardive dyskinesia. Intervention: L-dopa versus placebo.</td>
</tr>
<tr>
<td><strong>Hemnani 1982</strong></td>
<td>Allocation: randomised. Participants: people with a TD diagnosis.</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Cochrane Database of Systematic Reviews</strong></td>
<td></td>
</tr>
<tr>
<td>Jankovic 1982</td>
<td>Allocation: randomised.</td>
</tr>
<tr>
<td></td>
<td>Participants: various hyperkinetic movement disorders; dose of antipsychotic medication was not stable: &quot;All medications were either discontinued 1 week before the study or continued at the same dosage throughout the study&quot;</td>
</tr>
<tr>
<td></td>
<td>Participants: schizophrenia patients (Research Diagnostic Criteria; antipsychotic therapy; good physical condition). 5/11 were diagnosed as having TD. 1 TD patient also had tardive Tourette’s syndrome.</td>
</tr>
<tr>
<td></td>
<td>Interventions: apomorphine vs bromocriptine vs placebo.</td>
</tr>
<tr>
<td></td>
<td>Outcomes: no usable data, not reported for the first phase before crossing over. Study authors were contacted but no information was received. Consequently, this over 30-year-old study was excluded.</td>
</tr>
<tr>
<td>Kazamatsuri 1972</td>
<td>Allocation: not randomised.</td>
</tr>
<tr>
<td>Konig 1996</td>
<td>Allocation: not randomised, controlled clinical trial.</td>
</tr>
<tr>
<td></td>
<td>Participants: no TD ratings at baseline.</td>
</tr>
<tr>
<td></td>
<td>Interventions: amantadine vs biperiden.</td>
</tr>
<tr>
<td>Leblhuber 1987</td>
<td>Allocation: not randomised.</td>
</tr>
<tr>
<td>Levy 1984</td>
<td>Allocation: not randomised.</td>
</tr>
<tr>
<td></td>
<td>Participants: TD according to the criteria of Schooler and Kane, schizophrenia, schizoaffective disorder, major affective disorder and attention deficit disorder.</td>
</tr>
<tr>
<td></td>
<td>Intervention: physostigmine vs bromocriptine vs benztropine vs haloperidol for 1 day, then crossed over.</td>
</tr>
<tr>
<td></td>
<td>Outcomes: no usable data, not reported for the first phase before crossing over. Author was contacted but no information was received and this over 25 year-old-study was excluded.</td>
</tr>
<tr>
<td></td>
<td>Participants: psychiatric patients with persistent TD, N = 18, participants not on stable dose for a month at study entry.</td>
</tr>
<tr>
<td></td>
<td>Intervention: bromocriptine vs placebo.</td>
</tr>
<tr>
<td></td>
<td>Participants: chronic schizophrenics who had symptoms of severe persistent TD and who had been treated with antipsychotics.</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Intervention: L-dopa 500 mg + carbidopa 50 mg/d + low dose antipsychotics vs placebo + anticholinergic medication + low dose antipsychotic.</td>
</tr>
<tr>
<td></td>
<td>Outcomes: no outcome data could be used.</td>
</tr>
<tr>
<td></td>
<td>The study is over 25 years old and we were unable to identify contact details for the author.</td>
</tr>
<tr>
<td>Nasrallah 1986</td>
<td>Allocation: randomised, cross-over design.</td>
</tr>
<tr>
<td></td>
<td>Participants: psychiatric patients with persistent TD (Schooler and Kane criteria). N = 25.</td>
</tr>
<tr>
<td></td>
<td>Interventions: alpha-methyl-p-tyrosine (AMPT) vs L-dihydroxyphenylalanine vs choline chloride vs valproic acid vs hydroxytryptophan.</td>
</tr>
<tr>
<td></td>
<td>Outcomes: no usable data, not reported for the first phase before crossing over.</td>
</tr>
<tr>
<td></td>
<td>Authors were contacted and no reply was received. Consequently, this 30-year-old study was excluded.</td>
</tr>
<tr>
<td>NCT00310661 2006</td>
<td>Allocation: randomised.</td>
</tr>
<tr>
<td></td>
<td>Participants: people with Parkinson's disease, not tardive dyskinesia.</td>
</tr>
<tr>
<td>NCT00845000 2009</td>
<td>Allocation: randomised.</td>
</tr>
<tr>
<td></td>
<td>Participants: people with Parkinson's disease, not tardive dyskinesia.</td>
</tr>
<tr>
<td>O'Suilleabhain 2003</td>
<td>Allocation: randomised.</td>
</tr>
<tr>
<td></td>
<td>Participants: people with Huntington's disease, not tardive dyskinesia.</td>
</tr>
<tr>
<td>Reker 1982</td>
<td>Allocation: unclear.</td>
</tr>
<tr>
<td></td>
<td>Participants: &quot;psychiatric patients with tardive dyskinesia&quot;. Interventions: naloxone versus placebo.</td>
</tr>
<tr>
<td></td>
<td>Outcomes: no usable data.</td>
</tr>
<tr>
<td>Ringwald 1978</td>
<td>Allocation: not randomised.</td>
</tr>
<tr>
<td>Rondot 1987</td>
<td>Allocation: not randomised, double blind.</td>
</tr>
<tr>
<td></td>
<td>Participants: people with schizophrenia. Interventions: progabide for 6 weeks followed by placebo, no parallel arm.</td>
</tr>
<tr>
<td></td>
<td>Participants: people with schizophrenia with and without TD.</td>
</tr>
<tr>
<td></td>
<td>Interventions: biperiden vs amantadine.</td>
</tr>
<tr>
<td></td>
<td>Outcomes: unable to use data.</td>
</tr>
<tr>
<td></td>
<td>No up-to-date contact details were found for the study authors of this over 20-year-old study.</td>
</tr>
<tr>
<td>Smith 1977</td>
<td>Allocation: not randomised.</td>
</tr>
<tr>
<td></td>
<td>Participants: schizophrenia patients. Interventions: selegiline versus placebo.</td>
</tr>
<tr>
<td></td>
<td>Outcomes: no usable data, not reported for the first phase before crossing over.</td>
</tr>
<tr>
<td></td>
<td>We contacted study authors that replied, but no further data were available.</td>
</tr>
</tbody>
</table>
## Study

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
</table>
Participants: antipsychotic-free schizophrenia patients with TD.  
Interventions: CF 25-397 vs bromocriptine vs placebo.  
Outcomes: no usable data, not reported for the first phase before crossing over.  
Study authors were contacted but no information was received. Consequently, this over 35-year-old study was excluded. |
Participants: psychogeriatric patients treated with antipsychotics with severe dyskinesia for at least a year.  
Interventions: methyldopa versus placebo.  
Outcomes: no usable data, not reported for the first phase before crossing over.  
Study is over 40 years old, we were unable to identify contact details for the authors. |

---

**DATA AND ANALYSES**

### Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia (Review)

**Comparison 1. NORADRENERGIC DRUGS vs PLACEBO**

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Tardive dyskinesia: 1. No clinically important improvement - short term</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>0.33 [0.14, 0.80]</td>
</tr>
<tr>
<td>1.1 Alpha-methyldopa</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>0.33 [0.14, 0.80]</td>
</tr>
<tr>
<td>2 Tardive dyskinesia: 2. Not any improvement</td>
<td>2</td>
<td>55</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>0.91 [0.65, 1.27]</td>
</tr>
<tr>
<td>2.1 Alpha-methyldopa - short term</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>0.33 [0.02, 7.32]</td>
</tr>
<tr>
<td>2.2 Celiprolol - medium term</td>
<td>1</td>
<td>35</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>0.92 [0.66, 1.28]</td>
</tr>
<tr>
<td>3 Tardive dyskinesia: 3. Deterioration - short term</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.33 [0.02, 7.32]</td>
</tr>
<tr>
<td>3.1 Alpha-methyldopa</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.33 [0.02, 7.32]</td>
</tr>
<tr>
<td>4 Acceptability of treatment: Leaving the study early - medium term</td>
<td>1</td>
<td>35</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>5.28 [0.27, 102.58]</td>
</tr>
</tbody>
</table>
### Analysis 1.1. Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement - short term.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Noradrenergic n/N</th>
<th>Placebo n/N</th>
<th>Risk Ratio IV, Fixed, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1.1 Alpha-methyldopa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huang 1981</td>
<td>3/10</td>
<td>10/10</td>
<td>1.16</td>
<td>100%</td>
<td>0.33[0.02,7.32]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>10</td>
<td>10</td>
<td></td>
<td>100%</td>
<td>0.33[0.02,7.32]</td>
</tr>
</tbody>
</table>

Total events: 3 (Noradrenergic), 10 (Placebo)
Heterogeneity: Not applicable
Test for overall effect: Z=2.46 (P=0.01)

Favours Noradrenergic

### Analysis 1.2. Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Noradrenergic n/N</th>
<th>Placebo n/N</th>
<th>Risk Ratio IV, Fixed, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.2.1 Alpha-methyldopa - short term</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huang 1981</td>
<td>0/10</td>
<td>1/10</td>
<td>1.16</td>
<td>1.16%</td>
<td>0.33[0.02,7.32]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>10</td>
<td>10</td>
<td></td>
<td>1.16%</td>
<td>0.33[0.02,7.32]</td>
</tr>
</tbody>
</table>

Total events: 0 (Noradrenergic), 1 (Placebo)
Heterogeneity: Not applicable
Test for overall effect: Z=0.7(P=0.49)

1.2.2 Celiprolol - medium term

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Noradrenergic n/N</th>
<th>Placebo n/N</th>
<th>Risk Ratio IV, Fixed, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hebenstreit 1986</td>
<td>13/17</td>
<td>15/18</td>
<td></td>
<td>98.84%</td>
<td>0.92[0.66,1.28]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>17</td>
<td>18</td>
<td></td>
<td>98.84%</td>
<td>0.92[0.66,1.28]</td>
</tr>
</tbody>
</table>

Total events: 13 (Noradrenergic), 15 (Placebo)
Heterogeneity: Not applicable
Test for overall effect: Z=0.5 (P=0.62)

Total (95% CI) 27 28 100%

Favours Noradrenergic 0.91[0.65,1.27]
## Analysis 1.3. Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration - short term.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Noradrenergic n/N</th>
<th>Placebo n/N</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1.3.1 Alpha-methyldopa</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huang 1981</td>
<td>0/10</td>
<td>1/10</td>
<td></td>
<td>100%</td>
<td>0.33 [0.02, 7.32]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>10</td>
<td>10</td>
<td></td>
<td>100%</td>
<td>0.33 [0.02, 7.32]</td>
</tr>
<tr>
<td>Total events: 0 (Noradrenergic), 1 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.7 (P = 0.49)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>10</td>
<td>10</td>
<td></td>
<td>100%</td>
<td>0.33 [0.02, 7.32]</td>
</tr>
<tr>
<td>Total events: 0 (Noradrenergic), 1 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.7 (P = 0.49)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Analysis 1.4. Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 4 Acceptability of treatment: Leaving the study early - medium term.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Noradrenergic n/N</th>
<th>Placebo n/N</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1.4.1 Celiprolol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hebenstreit 1986</td>
<td>2/17</td>
<td>0/18</td>
<td></td>
<td>100%</td>
<td>5.28 [0.27, 102.58]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>17</td>
<td>18</td>
<td></td>
<td>100%</td>
<td>5.28 [0.27, 102.58]</td>
</tr>
<tr>
<td>Total events: 2 (Noradrenergic), 0 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 1.1 (P = 0.27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>17</td>
<td>18</td>
<td></td>
<td>100%</td>
<td>5.28 [0.27, 102.58]</td>
</tr>
<tr>
<td>Total events: 2 (Noradrenergic), 0 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 1.1 (P = 0.27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 1.5. Comparison 1 NORADRENERGIC DRUGS vs PLACEBO, Outcome 5 Quality of life: No improvement - medium term.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Noradrenergic n/N</th>
<th>Placebo n/N</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1.5.1 Celiprolol</strong> Hebenstreit 1986</td>
<td>14/17</td>
<td>17/18</td>
<td>100%</td>
<td>0.87 [0.68, 1.12]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>17</td>
<td>18</td>
<td>100%</td>
<td>0.87 [0.68, 1.12]</td>
<td></td>
</tr>
<tr>
<td>Total events: 14 (Noradrenergic), 17 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z =1.09 (P =0.28)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>17</td>
<td>18</td>
<td>100%</td>
<td>0.87 [0.68, 1.12]</td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z =1.09 (P =0.28)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Favours Noradrenergic 0.5 0.7 1 1.5 2 Favours placebo

### Comparison 2. NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Tardive dyskinesia: 1. No clinically important improvement - short term</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.6 [0.19, 1.86]</td>
</tr>
<tr>
<td>1.1 Alpha-methyldopa versus Reserpine</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.6 [0.19, 1.86]</td>
</tr>
<tr>
<td>2 Tardive dyskinesia: 2. Not any improvement - short term</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>2.1 Alpha-methyldopa versus Reserpine</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>3 Tardive dyskinesia: 3. Deterioration - short term</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>3.1 Alpha-methyldopa versus Reserpine</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
</tbody>
</table>

### Analysis 2.1. Comparison 2 NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement - short term.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Alpha-methyldopa n/N</th>
<th>Reserpine n/N</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2.1.1 Alpha-methyldopa versus Reserpine</strong> Huang 1981</td>
<td>3/10</td>
<td>5/10</td>
<td>100%</td>
<td>0.6 [0.19, 1.86]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>10</td>
<td>10</td>
<td>100%</td>
<td>0.6 [0.19, 1.86]</td>
<td></td>
</tr>
<tr>
<td>Total events: 3 (Alpha-methyldopa), 5 (Reserpine)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 2.2. Comparison 2 NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS, Outcome 2 Tardive dyskinesia: 2. Not any improvement - short term.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Alpha-methyl-dopa n/N</th>
<th>Reserpine n/N</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huang 1981</td>
<td>0/10</td>
<td>0/10</td>
<td></td>
<td>Not estimable</td>
<td>Not estimable</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>10</td>
<td>10</td>
<td></td>
<td>Not estimable</td>
<td>Not estimable</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>10</td>
<td>10</td>
<td></td>
<td>Not estimable</td>
<td>Not estimable</td>
</tr>
</tbody>
</table>

Favours Alpha-methyl-dopa

### Analysis 2.3. Comparison 2 NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS, Outcome 3 Tardive dyskinesia: 3. Deterioration - short term.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Alpha-methyl-dopa n/N</th>
<th>Reserpine n/N</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huang 1981</td>
<td>0/10</td>
<td>0/10</td>
<td></td>
<td>Not estimable</td>
<td>Not estimable</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>10</td>
<td>10</td>
<td></td>
<td>Not estimable</td>
<td>Not estimable</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>10</td>
<td>10</td>
<td></td>
<td>Not estimable</td>
<td>Not estimable</td>
</tr>
</tbody>
</table>

Favours Alpha-methyl-dopa
### Comparison 3. DOPAMINERGIC DRUGS vs PLACEBO

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Tardive dyskinesia: 1. No clinically important improvement</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>0.52 [0.29, 0.96]</td>
</tr>
<tr>
<td>1.1 Reserpine - short term</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>0.52 [0.29, 0.96]</td>
</tr>
<tr>
<td>2 Tardive dyskinesia: 2. Not any improvement</td>
<td>3</td>
<td>57</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.60 [0.35, 1.03]</td>
</tr>
<tr>
<td>2.1 Reserpine - short term</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.33 [0.02, 7.32]</td>
</tr>
<tr>
<td>2.2 L-DOPA - short term</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.67 [0.35, 1.27]</td>
</tr>
<tr>
<td>2.3 Carbidopa/levodopa - medium term</td>
<td>1</td>
<td>17</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.59 [0.26, 1.36]</td>
</tr>
<tr>
<td>3 Tardive dyskinesia: 3. Deterioration</td>
<td>2</td>
<td>37</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.18 [0.35, 3.99]</td>
</tr>
<tr>
<td>3.1 Reserpine - short term</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.33 [0.02, 7.32]</td>
</tr>
<tr>
<td>3.2 Carbidopa/levodopa - medium term</td>
<td>1</td>
<td>17</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.78 [0.44, 7.25]</td>
</tr>
<tr>
<td>4 Mental state: Deterioration - medium term</td>
<td>1</td>
<td></td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>Subtotals only</td>
</tr>
<tr>
<td>4.1 Oxyperpine</td>
<td>1</td>
<td>42</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>2.2 [0.22, 22.45]</td>
</tr>
<tr>
<td>5 Acceptability of treatment: Leaving the study early</td>
<td>6</td>
<td>163</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.29 [0.65, 2.54]</td>
</tr>
<tr>
<td>5.1 Amantadine - short term</td>
<td>1</td>
<td>22</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>5.2 Bromocriptine - short term</td>
<td>1</td>
<td>20</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>5.3 Tiapride - short term</td>
<td>1</td>
<td>12</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>5.4 Tiapride - medium term</td>
<td>1</td>
<td>50</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>5.5 Oxyperpine - medium term</td>
<td>1</td>
<td>42</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.73 [0.83, 3.58]</td>
</tr>
<tr>
<td>5.6 Carbidopa/levodopa - medium term</td>
<td>1</td>
<td>17</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.18 [0.01, 3.27]</td>
</tr>
</tbody>
</table>
### Analysis 3.1. Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO,
Outcome 1 Tardive dyskinesia: 1. No clinically important improvement.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dopaminergic</th>
<th>Placebo</th>
<th>Risk Ratio IV, Fixed, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1.1 Reserpine - short term</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huang 1981</td>
<td>5/10</td>
<td>10/10</td>
<td>100%</td>
<td>0.52 [0.29, 0.96]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>10</td>
<td>10</td>
<td>100%</td>
<td>0.52 [0.29, 0.96]</td>
<td></td>
</tr>
<tr>
<td>Total events: 5 (Dopaminergic), 10 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z =2.1 (P =0.04)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>10</td>
<td>10</td>
<td>100%</td>
<td>0.52 [0.29, 0.96]</td>
<td></td>
</tr>
<tr>
<td>Total events: 5 (Dopaminergic), 10 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z =2.1 (P =0.04)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

### Analysis 3.2. Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO,
Outcome 2 Tardive dyskinesia: 2. Not any improvement.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dopaminergic</th>
<th>Placebo</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.2.1 Reserpine - short term</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huang 1981</td>
<td>0/10</td>
<td>1/10</td>
<td>10.83%</td>
<td>0.33 [0.02, 7.32]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>10</td>
<td>10</td>
<td>10.83%</td>
<td>0.33 [0.02, 7.32]</td>
<td></td>
</tr>
<tr>
<td>Total events: 0 (Dopaminergic), 1 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z =0.7 (P =0.49)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.2.2 L-DOPA - short term</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karniol 1983</td>
<td>8/15</td>
<td>4/5</td>
<td>43.31%</td>
<td>0.67 [0.35, 1.27]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>15</td>
<td>5</td>
<td>43.31%</td>
<td>0.67 [0.35, 1.27]</td>
<td></td>
</tr>
<tr>
<td>Total events: 8 (Dopaminergic), 4 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z =1.23 (P =0.22)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.2.3 Carbidopa/levodopa - medium term</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simpson 1988</td>
<td>4/9</td>
<td>6/8</td>
<td>45.86%</td>
<td>0.59 [0.26, 1.36]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>9</td>
<td>8</td>
<td>45.86%</td>
<td>0.59 [0.26, 1.36]</td>
<td></td>
</tr>
<tr>
<td>Total events: 4 (Dopaminergic), 6 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z =1.23 (P =0.22)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total events: 12 (Dopaminergic), 11 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Tau²=0; Chi²=0.25, df=2 (P =0.88); I²=0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z =1.86 (P =0.06)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup differences: Chi²=0.21, df=1 (P =0.63), I²=0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>34</td>
<td>23</td>
<td>100%</td>
<td>0.6 [0.35, 1.03]</td>
<td></td>
</tr>
</tbody>
</table>
Analysis 3.3. Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dopaminergic</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Fixed, 95% CI</td>
<td></td>
</tr>
<tr>
<td>3.3.1 Reserpine - short term</td>
<td>0/10</td>
<td>1/10</td>
<td>41.46%</td>
<td>0.33[0.02,7.32]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>10</td>
<td>10</td>
<td>41.46%</td>
<td>0.33[0.02,7.32]</td>
</tr>
<tr>
<td>Total events: 0 (Dopaminergic), 1 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z=0.7(P=0.49)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dopaminergic</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Fixed, 95% CI</td>
<td></td>
</tr>
<tr>
<td>3.3.2 Carbidopa/levodopa - medium term</td>
<td>4/9</td>
<td>2/8</td>
<td>58.54%</td>
<td>1.78[0.44,7.25]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>9</td>
<td>8</td>
<td>58.54%</td>
<td>1.78[0.44,7.25]</td>
</tr>
<tr>
<td>Total events: 4 (Dopaminergic), 2 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z=0.8(P=0.42)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dopaminergic</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Fixed, 95% CI</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>19</td>
<td>18</td>
<td>100%</td>
<td>1.18[0.35,3.99]</td>
</tr>
<tr>
<td>Total events: 4 (Dopaminergic), 3 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Tau^2=0; Chi^2=0.97, df=1(P=0.32); I^2=0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z=0.26(P=0.79)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup differences: Chi^2=0.93, df=1 (P=0.33), I^2=0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Favours dopaminergic 0.01 0.1 1 10 100 0.01 0.1 1 10 100

Analysis 3.4. Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 4 Mental state: Deterioration - medium term.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dopaminergic</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>IV, Fixed, 95% CI</td>
<td></td>
</tr>
<tr>
<td>3.4.1 Oxypertine</td>
<td>2/20</td>
<td>1/22</td>
<td>100%</td>
<td>2.2[0.22,22.45]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>20</td>
<td>22</td>
<td>100%</td>
<td>2.2[0.22,22.45]</td>
</tr>
<tr>
<td>Total events: 2 (Dopaminergic), 1 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z=0.67(P=0.51)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Favours dopaminergic 0.1 0.2 0.5 1 2 5 10 0.1 0.2 0.5 1 2 5 10

Analysis 3.5. Comparison 3 DOPAMINERGIC DRUGS vs PLACEBO, Outcome 5 Acceptability of treatment: Leaving the study early.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dopaminergic</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Fixed, 95% CI</td>
<td></td>
</tr>
<tr>
<td>3.5.1 Amantadine - short term</td>
<td>0/11</td>
<td>0/11</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>11</td>
<td>11</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Total events: 0 (Dopaminergic), 0 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Favours dopaminergic 0.005 0.1 1 10 200 0.005 0.1 1 10 200

Favours placebo
<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dopaminergic</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Fixed, 95% CI</td>
<td></td>
<td>M-H, Fixed, 95% CI</td>
</tr>
<tr>
<td><strong>3.5.2 Bromocriptine - short term</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen 1995</td>
<td>0/10</td>
<td>0/10</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>10</td>
<td>10</td>
<td>Not estimable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total events: 0 (Dopaminergic), 0 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>3.5.3 Tiapride - short term</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buruma 1982</td>
<td>0/7</td>
<td>0/5</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>7</td>
<td>5</td>
<td>Not estimable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total events: 0 (Dopaminergic), 0 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>3.5.4 Tiapride - medium term</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rust 1984</td>
<td>0/25</td>
<td>0/25</td>
<td>Not estimable</td>
<td></td>
<td>Not estimable</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>25</td>
<td>25</td>
<td>Not estimable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total events: 0 (Dopaminergic), 0 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>3.5.5 Oxypertine - medium term</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soni 1986</td>
<td>11/20</td>
<td>7/22</td>
<td>71.7% 1.73[0.83,3.58]</td>
<td></td>
<td>71.7% 1.73[0.83,3.58]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>20</td>
<td>22</td>
<td>71.7% 1.73[0.83,3.58]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total events: 11 (Dopaminergic), 7 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z=1.47(P=0.14)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>3.5.6 Carbidopa/levodopa - medium term</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simpson 1988</td>
<td>0/9</td>
<td>2/8</td>
<td>28.3% 0.18[0.01,3.27]</td>
<td></td>
<td>28.3% 0.18[0.01,3.27]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>9</td>
<td>8</td>
<td>28.3% 0.18[0.01,3.27]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total events: 0 (Dopaminergic), 2 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z=1.16(P=0.25)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>82</td>
<td>81</td>
<td>100% 1.29[0.65,2.54]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total events: 11 (Dopaminergic), 9 (Placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Tau^2=0; Chi^2=2.39, df=1(P=0.12); I^2=58.17%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z=0.74(P=0.46)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup differences: Chi^2=2.2, df=1 (P=0.14), I^2=54.52%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Favours dopaminergic**

<table>
<thead>
<tr>
<th>Favours dopaminergic</th>
<th>0.005</th>
<th>0.3</th>
<th>1</th>
<th>10</th>
<th>200</th>
<th>Favours placebo</th>
</tr>
</thead>
</table>

**Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia (Review)**

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
## Comparison 4. DOPAMINERGIC DRUGS vs OTHER DRUGS

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Tardive dyskinesia: 1. No clinically important improvement - medium term</td>
<td>1</td>
<td>13</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>0.93 [0.45, 1.95]</td>
</tr>
<tr>
<td>1.1 Tetrabenazine vs Haloperidol</td>
<td>1</td>
<td>13</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>0.93 [0.45, 1.95]</td>
</tr>
<tr>
<td>2 Tardive dyskinesia: 2. Not any improvement - medium term</td>
<td>1</td>
<td>13</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>0.39 [0.05, 2.83]</td>
</tr>
<tr>
<td>2.1 Tetrabenazine vs Haloperidol</td>
<td>1</td>
<td>13</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>0.39 [0.05, 2.83]</td>
</tr>
<tr>
<td>3 Tardive dyskinesia: 3. Deterioration - medium term</td>
<td>1</td>
<td>13</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>1.17 [0.09, 14.92]</td>
</tr>
<tr>
<td>3.1 Tetrabenazine vs Haloperidol</td>
<td>1</td>
<td>13</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>1.17 [0.09, 14.92]</td>
</tr>
<tr>
<td>4 Acceptability of treatment: Leaving the study early - medium term</td>
<td>1</td>
<td>13</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>0.23 [0.01, 4.00]</td>
</tr>
<tr>
<td>4.1 Tetrabenazine vs Haloperidol</td>
<td>1</td>
<td>13</td>
<td>Risk Ratio (IV, Fixed, 95% CI)</td>
<td>0.23 [0.01, 4.00]</td>
</tr>
</tbody>
</table>

### Analysis 4.1. Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement - medium term.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Tetrabenazine n/N</th>
<th>Haloperidol n/N</th>
<th>Risk Ratio IV, Fixed, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1.1 Tetrabenazine vs Haloperidol</td>
<td>4/6</td>
<td>5/7</td>
<td>0.93 [0.45, 1.95]</td>
<td>100%</td>
<td>0.93 [0.45, 1.95]</td>
</tr>
</tbody>
</table>

Total events: 4 (Tetrabenazine), 5 (Haloperidol)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.18 (P = 0.85)

### Analysis 4.2. Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 2 Tardive dyskinesia: 2. Not any improvement - medium term.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Tetrabenazine n/N</th>
<th>Haloperidol n/N</th>
<th>Risk Ratio IV, Fixed, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2.1 Tetrabenazine vs Haloperidol</td>
<td>1</td>
<td>13</td>
<td>0.23 [0.01, 4.00]</td>
<td>100%</td>
<td>0.23 [0.01, 4.00]</td>
</tr>
</tbody>
</table>

Total events: 4 (Tetrabenazine), 5 (Haloperidol)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.18 (P = 0.85)
### Analysis 4.3. Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 3 Tardive dyskinesia: 3. Deterioration - medium term.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Tetrabenazine</th>
<th>Haloperidol</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>IV, Fixed, 95% CI</td>
<td></td>
<td>IV, Fixed, 95% CI</td>
</tr>
<tr>
<td>Kazamatsuri 1973</td>
<td>1/6</td>
<td>3/7</td>
<td></td>
<td>100%</td>
<td>0.39[0.05,2.83]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>6</td>
<td>7</td>
<td></td>
<td>100%</td>
<td>0.39[0.05,2.83]</td>
</tr>
<tr>
<td>Total events: 1 (Tetrabenazine), 3 (Haloperidol)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z=0.93(P=0.35)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Analysis 4.4. Comparison 4 DOPAMINERGIC DRUGS vs OTHER DRUGS, Outcome 4 Acceptability of treatment: Leaving the study early - medium term.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Tetrabenazine</th>
<th>Haloperidol</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>IV, Fixed, 95% CI</td>
<td></td>
<td>IV, Fixed, 95% CI</td>
</tr>
<tr>
<td>Kazamatsuri 1973</td>
<td>0/6</td>
<td>2/7</td>
<td></td>
<td>100%</td>
<td>0.23[0.01,4]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>6</td>
<td>7</td>
<td></td>
<td>100%</td>
<td>0.23[0.01,4]</td>
</tr>
<tr>
<td>Total events: 0 (Tetrabenazine), 2 (Haloperidol)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z=1.01(P=0.31)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Kazamatsuri 1973: n=6/7, Risk Ratio: 0.39[0.05,2.83] (P=0.35)

Subtotal: n=6/7, Risk Ratio: 0.39[0.05,2.83] (P=0.35)

Total events: 1 (Tetrabenazine), 3 (Haloperidol)
Heterogeneity: Not applicable
Test for overall effect: Z=0.93(P=0.35)

Kazamatsuri 1973: n=0/6, Risk Ratio: 0.23[0.01,4] (P=0.31)

Subtotal: n=6/7, Risk Ratio: 0.23[0.01,4] (P=0.31)

Total events: 0 (Tetrabenazine), 2 (Haloperidol)
Heterogeneity: Not applicable
Test for overall effect: Z=1.01(P=0.31)
**Table 1. Other reviews in the series**

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticholinergic medication</td>
<td>Soares-Weiser 1997</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>Bhoopathi 2006</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>Essali 2011</td>
</tr>
<tr>
<td>Cholinergic medication</td>
<td>Tammenmaa 2002</td>
</tr>
<tr>
<td>Gamma-aminobutyric acid agonists</td>
<td>Alabed 2011</td>
</tr>
<tr>
<td>Miscellaneous treatments</td>
<td>Soares-Weiser 2003</td>
</tr>
<tr>
<td>Neuroleptic reduction and/or cessation and neuroleptics</td>
<td>Soares-Weiser 2006</td>
</tr>
<tr>
<td>Non-neuroleptic catecholaminergic drugs</td>
<td>This review</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>Soares-Weiser 2011</td>
</tr>
</tbody>
</table>

**Table 2. Suggestions for design of future studies**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Allocation: randomised, with sequence generation and concealment of allocation clearly described.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Blindness: double, tested.</td>
</tr>
<tr>
<td></td>
<td>Duration: 12 months beyond end of intervention at least.</td>
</tr>
<tr>
<td></td>
<td>Raters: independent.</td>
</tr>
<tr>
<td>Participants</td>
<td>People with antipsychotic-induced tardive dyskinesia.*</td>
</tr>
<tr>
<td></td>
<td>Age: any.</td>
</tr>
<tr>
<td></td>
<td>Sex: both.</td>
</tr>
<tr>
<td></td>
<td>History: any.</td>
</tr>
<tr>
<td></td>
<td>N = 300.**</td>
</tr>
<tr>
<td></td>
<td>2. Placebo: N = 150.</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Tardive dyskinesia: any clinically important improvement in TD, any improvement, deterioration.***</td>
</tr>
<tr>
<td></td>
<td>Adverse effects: no clinically significant extrapyramidal adverse effects - any time period***, use of any antiparkinsonism drugs, other important adverse events.</td>
</tr>
<tr>
<td></td>
<td>Leaving the study early.</td>
</tr>
<tr>
<td></td>
<td>Service outcomes: admitted, number of admissions, length of hospitalisation, contacts with psychiatric services.</td>
</tr>
<tr>
<td></td>
<td>Compliance with drugs.</td>
</tr>
<tr>
<td></td>
<td>General state: relapse, frequency and intensity of minor and major exacerbations.</td>
</tr>
<tr>
<td></td>
<td>Social confidence, social inclusion, social networks, or personalised quality of life: binary measure</td>
</tr>
<tr>
<td></td>
<td>Distress among relatives: binary measure.</td>
</tr>
<tr>
<td></td>
<td>Burden on family: binary measure.</td>
</tr>
</tbody>
</table>
Table 2. Suggestions for design of future studies (Continued)

Notes
* This could be diagnosed by clinical decision. If funds were permitting all participants could be screened using operational criteria, otherwise a random sample should suffice.

** Size of study with sufficient power to highlight about a 10% difference between groups for primary outcome.

*** Primary outcome. The same applies to the measure of primary outcome as for diagnosis. Not everyone may need to have operational criteria applied if clinical impression is proved to be accurate.

APPENDICES

Appendix 1. Previous methods

Methods

Criteria for considering studies for this review

Types of studies

We included all relevant randomised controlled trials. Where a trial was described as 'double-blind' but it was implied that the study was randomised, we included these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes (see types of outcome measures) when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only used clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.

Types of participants

People with schizophrenia or any other chronic mental illnesses, diagnosed by any criteria, irrespective of gender, age or nationality who:

i. required the use of neuroleptics for more than three months;

ii. developed tardive dyskinesia (diagnosed by any criteria) during neuroleptic treatment; and

iii. for whom the dose of neuroleptic medication had been stable for one month or more before the trial.

Types of interventions

A. Noradrenergic drugs

i. Celiprolol, clonidine, disulfiram, fusaric acid, methyldopa, pindolol, propanolol, oxprenolol or yohimbine, compared with placebo or no intervention.

B. Dopaminergic drugs

i. The dopamine receptor agonists (apomorphine, bromocriptine, CF25-397, dopamine, hyergine, lisuride);

ii. the dopamine receptor antagonists (AMTP, oxiperomide, metoclopramide, papaverine, tiapride);

iii. the dopamine depleter drugs (oxypertine, reserpine, tetrabenazine);

iv. drugs that increase the release (amantadine, amphetamine) or production (L-dopa) of dopamine; all compared with placebo or no intervention.

Types of outcome measures

1. Tardive dyskinesia

1.1. No clinically important change in tardive dyskinesia*

1.2. Not any change in tardive dyskinesia

1.3. Average endpoint tardive dyskinesia score

1.4. Average change in tardive dyskinesia scores

2. Mental state

2.1. No clinically important change in general mental state*

2.2. Not any change in general mental state

2.3. Average endpoint general mental state score

2.4. Average change in general mental state scores

2.5. No clinically important change in specific symptoms

2.6. Not any change in specific symptoms

2.7. Average endpoint specific symptom score
2.8. Average change in specific symptom scores

3. Adverse effects
3.1. Clinically important general adverse effects*
3.2. Any general adverse effects
3.3. Average endpoint general adverse effect score
3.4. Average change in general adverse effect scores
3.5. Clinically important change in specific adverse effects
3.6. Any change in specific adverse effects
3.7. Average endpoint specific adverse effects
3.8. Average change in specific adverse effects

4. Leaving the study early
4.1. For specific reasons
4.2. For general reasons*

* Primary outcomes

When possible, outcomes were grouped into time periods - short term (less than 6 weeks), medium term (between 6 weeks and 6 months) and long term (over 6 months).

Search methods for identification of studies

1. Electronic searching for the update (2005)
   1.1. We identified relevant randomised trials by searching the Cochrane Schizophrenia Group's register using the phrase:

   SELECT tblStudy.CRGStudyID FROM tblStudy WHERE tblStudy.CRGStudyID IN (SELECT tblStudyIntervention.CRGStudyID FROM tblIntervention INNER JOIN tblStudyIntervention ON tblIntervention.InterventionID=tblStudyIntervention.InterventionID WHERE InterventionDescription Like '*amantadin*' OR InterventionDescription Like '*amphetamin*' OR InterventionDescription Like '*apomorphin*' OR InterventionDescription Like '*bromcriptin*' OR InterventionDescription Like '*celiprolol*' OR InterventionDescription Like '*clonidin*' OR InterventionDescription Like '*dopa*' OR InterventionDescription Like '*disulfiram*' OR InterventionDescription Like '*fusaric*' OR InterventionDescription Like '*hydergin*' OR InterventionDescription Like '*lisurid*' OR InterventionDescription Like '*metocloprimad*' OR InterventionDescription Like '*oxiperoxid*' OR InterventionDescription Like '*oxipertine*' OR InterventionDescription Like '*papaverin*' OR InterventionDescription Like '*propaprin*' OR InterventionDescription Like '*propranolol*' OR InterventionDescription Like '*reserpine*' OR InterventionDescription Like '*tetra binezine*' OR InterventionDescription Like '*tiaprid** OR InterventionDescription Like '*yohimb*');

2. Details of previous searches:

We identified relevant randomised trials by searching several electronic databases (Biological Abstracts, the Cochrane Schizophrenia Group's Register of trials, EMBASE, LILACS, MEDLINE, PsycLIT and SCISEARCH).

2.1. Biological Abstracts
   We searched Biological Abstracts (January 1982 to May 1995) using the Cochrane Schizophrenia Group's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:

   [and ((tardive near (dyskinesia * or disk ine*) or (abnormal near movement* near disorder*) or (involuntary* near movement*)) and (amantadine or amphetamine or AMTP or apomorphine or bromocriptine or celiprolor or CF?25397 or clonidine or *dopa* or disulfiram or fusaric or hydergine or lisuride or methylpopa or metoclopramide or oxiperoxide or oxporenol or oxyptertine or papaverine or pindolol or propanolol or reserpine or tetrabenazine or tiaprid or yohimbine)])

2.2. The Cochrane Schizophrenia Group's Register (1997)

We searched The Cochrane Schizophrenia Group's register using the phrase:

[(dyskinesia) and (amantadine or amphetamine or AMTP or apomorphine or bromocriptine or celiprolor or CF?25397 or clonidine or *dopa* or disulfiram or fusaric or hydergine or lisuride or methylpopa or metoclopramide or oxiperoxide or oxporenol or oxyptertine or papaverine or pindolol or propanolol or reserpine or tetrabenazine or tiaprid or yohimbine)]

2.3. EMBASE

We searched EMBASE (January 1980 to May 1995) using the Cochrane Schizophrenia Group's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:

[(tardive dyskinesia in thesaurus -subheadings, prevention, drug therapy, side effect and therapy) or (neuroleptic dyskinesia in thesaurus - all subheadings) or (tardive or dyskinesia*) or (movement* or disorder*) or (abnormal or movement* or disorder*)] and (amantadine or amphetamine or AMTP or apomorphine or bromocriptine or celiprolor or CF?25397 or clonidine or *dopa* or disulfiram or...]

Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia (Review)

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
fusaric or hydrgine or lisuride or methyltdopa or metoclopramide or oxiperoxide or oxprenolol or oxpyertine or papaverine or pindolol or propanolol or reserpine or tetrabenzine or tiapride or yohimbine)

2.4. LILACS
We searched LILACS (January 1982 to September 1996) using the Cochrane Schizophrenia Group's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:

[and ((tardive or (dyskinesia* or dyskinesia*)) or (drug induced movement disorders in thesaurus)) and (amantadine or amphetamine or AMTP or apomorphine or bromocriptine or celiprolol or CF725397 or clonidine or *dopa* or disulfiram or fusaric or hydrgine or lisuride or methyltdopa or metoclopramide or oxiperoxide or oxprenolol or oxpyertine or papaverine or pindolol or propanolol or reserpine or tetrabenzine or tiapride or yohimbine)]

2.5. MEDLINE
We searched MEDLINE (January 1966 to May 1995) using the Cochrane Schizophrenia Group's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:

[and ((movement-disorders in MeSH / explode all subheadings) or (anti-dyskinesia-agents in MeSH / explode all subheadings) or (dyskinesia-drug-induced in MeSH / explode all subheadings) and (psychosis in MeSH / explode all subheadings) or (schizophrenic disorders in MeSH / explode all subheadings) or (tardive near (dyskine* or diskine*)) or (abnormal* near movement* near disorder*) or (involutar* near movement*)) and (amantadine or amphetamine or AMTP or apomorphine or bromocriptine or celiprolol or CF725397 or clonidine or "dopa" or disulfiram or fusaric or hydrgine or lisuride or methyltdopa or metoclopramide or oxiperoxide or oxprenolol or oxpyertine or papaverine or pindolol or propanolol or reserpine or tetrabenzine or tiapride or yohimbine)]

2.6. PsycLIT
We searched PsycLIT (January 1974 to May 1995) using the Cochrane Schizophrenia Group's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:

[and ((explode movement-disorders in DE) or (explode tardive-dyskinesia in DE) or (tardive near (dyskine* or diskine*) or (abnormal* near movement* near disorder*) or (involutar* near movement*)) and (amantadine or amphetamine or AMTP or apomorphine or bromocriptine or celiprolol or CF725397 or clonidine or "dopa" or disulfiram or fusaric or hydrgine or lisuride or methyltdopa or metoclopramide or oxiperoxide or oxprenolol or oxpyertine or papaverine or pindolol or propanolol or reserpine or tetrabenzine or tiapride or yohimbine)]

3. SCISEARCH - Science Citation Index
We sought each of the included studies as a citation on the SCISEARCH database. We inspected reports of articles that had cited these studies in order to identify further trials.

4. Reference searching
We inspected the references of all identified studies for more studies.

5. Personal contact
We contacted the first author of each included study for information regarding unpublished trials.

Data collection and analysis

1. Selection of trials
We downloaded citations from electronic sources including details of author, institution or journal of publication. We (HGE) inspected all reports. These were then re-inspected by (KS and JR) in order to ensure reliable selection. Any disagreement was resolved by discussion, and where there was still doubt we acquired the full article for further inspection. Once the full articles were obtained, we (HGE, KS and JR) decided whether the studies met the review criteria. Whenever we could not resolve any disagreement by discussion, we sought further information and added these trials to the list of those awaiting assessment.

2. Assessment of methodological quality
The methodological quality of all included trials was assessed using the criteria described in the Cochrane Handbook (Higgins 2005) and the Jadad Scale (Jadad 1996). The former is based on the evidence of a strong relationship between allocation concealment and direction of effect (Schulz 1995). The categories are defined below:

A. Low risk of bias (adequate allocation concealment)
B. Moderate risk of bias (some doubt about the results)
C. High risk of bias (inadequate allocation concealment). For the purpose of the analysis in this review, trials were included if they met the Cochrane Handbook criteria A or B.

The Jadad Scale measures a wider range of factors that impact on the quality of a trial. The scale includes three items:
4.4.2 Cluster trials
reporting only change data for endpoint figures. We reported non-normally distributed data in the 'Other data types' tables. This much of the published change data were excluded, but argue that endpoint data is more clinically relevant and that if change data were to be presented along with endpoint data it would be given undeserved equal prominence. We are contacting authors of studies reporting only change data for endpoint figures. We reported non-normally distributed data in the 'Other data types' tables.

4.3 Dichotomous - yes/no - data
We analysed data on an intention to treat analysis. On the condition that more than 60% of people completed the study, we counted everyone allocated to the intervention regardless of whether they completed the follow up. We assumed that those who dropped out had the negative outcome, with the exception of death. Where possible we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut off points on rating scales and dividing subjects accordingly into 'clinically improved' or 'not clinically improved'. If the authors of a study had used a predefined cut off point for determining clinical effectiveness we used the reviewers' criteria where appropriate. Otherwise we generally assumed that if there had been a 50% reduction in a scale-derived score, this could be considered as a clinically significant response. Similarly, a rating of 'at least much improved' according to the Clinical Global Impression Scale (Guy 1970) could be considered as a clinically significant response.

4.4 Continuous data
4.4.1 Normally distributed data: data on continuous outcomes are frequently skewed, the mean not being the centre of the distribution. The statistics for meta-analysis are thought to be able to cope with some skew, but were formulated for parametric data. To avoid this potential pitfall we applied the following standards to all data before inclusion: (a) standard deviations and means were reported or obtained from authors and (b) for data with finite limits, such as endpoint scale data, the standard deviation (SD), when multiplied by two, was less than the mean. Otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (Altman 1996). We reported data that did not meet the first or second standard in the 'other data' tables. If a scale starts from a positive value (such as PANSS, which can have values from 30-210) the calculation described above should be modified to take the scale starting point into account. In these cases skewness is present if 2SD>(S-Smin), where S is the mean score and Smin is the minimum score.

For change data (endpoint minus baseline), the situation is even more problematic. In the absence of individual patient data it is impossible to know if data are skewed, though this is likely. After consulting the ALLSTAT electronic statistics mailing list, we presented change data in MetaView in order to summarise available information. In doing this, it is assumed either that data were not skewed or that the analyses could cope with the unknown degree of skewness. Without individual patient data it is impossible to test this assumption. Where both change and endpoint data were available for the same outcome category only endpoint data are presented. We acknowledge that by doing this much of the published change data were excluded, but argue that endpoint data is more clinically relevant and that if change data were to be presented along with endpoint data it would be given undeserved equal prominence. We are contacting authors of studies reporting only change data for endpoint figures. We reported non-normally distributed data in the 'Other data types' tables.

4.2 Incomplete data
With the exception of the outcome of leaving the study early, we did not include trial outcomes if more than 40% of people were not reported in the final analysis.

4.4.2 Cluster trials
Within the publish ed change data were excluded, but argue that endpoint data is more clinically relevant and that if change data could cope with the unknow n degree of skewness. Without individual patient data it is impossible to test this assumption. Where both change and endpoint data were available for the same outcome category only endpoint data are presented. We acknowledge that by doing this much of the published change data were excluded, but argue that endpoint data is more clinically relevant and that if change data were to be presented along with endpoint data it would be given undeserved equal prominence. We are contacting authors of studies reporting only change data for endpoint figures. We reported non-normally distributed data in the 'Other data types' tables.
Studies increasingly employ ‘cluster randomisation’ (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a ‘unit of analysis’ error (Divine 1992) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (Bland 1997, Gulliford 1999).

Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (Gulliford 1999). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.

We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a ‘design effect’. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect = 1+(m-1)*ICC] (Donner 2002). If the ICC was not reported it was assumed to be 0.1 (Ukoumunne 1999).

4.4.2 Rating scales: A wide range of instruments is available to measure mental health outcomes. These instruments vary in quality and many are not valid, or even ad hoc. For outcome instruments some minimum standards have to be set. It has been shown that the use of rating scales which had not been described in a peer-reviewed journal (Marshall 2000) is associated with bias and therefore we excluded the results of such scales. Furthermore, the instrument should either be a self report or be completed by an independent rater or relative (not the therapist), and the instrument could be considered a global assessment of an area of functioning. However, as it was expected that therapists would frequently also be the rater, we did include such data but commented on this data as ‘prone to bias’.

4.4.3 Summary statistic
For continuous outcomes we estimated the weighted mean difference (WMD) between groups, again based on the random effects model, as it takes into account any differences between studies even if there is no statistically significant heterogeneity. We inspected data to see if analysis using a fixed effects model made any substantive difference when the results were not statistically significantly heterogeneous. Whenever possible, we took the opportunity to make direct comparisons between trials that used the same measurement instrument to quantify specific outcomes. Where continuous data were presented from different scales rating the same effect, we presented both sets of data and the general direction of effect was inspected.

5. Heterogeneity
Firstly, we considered all of the included studies within any comparison to judge clinical heterogeneity. Then we visually inspected graphs used to investigate the possibility of statistical heterogeneity and supplemented this by using, primarily, the I-squared statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate was greater than or equal to 75%, we interpreted this as indicating the presence of high levels of heterogeneity (Higgins 2003). If inconsistency was high, we did not summate the data, but presented it separately and reasons for heterogeneity were investigated.

6. Addressing publication bias
We entered all data from selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias.

7. Sensitivity analyses
We analysed the effect of including studies with high attrition rates in the sensitivity analysis.

8. General
Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for the treatment groups.

WHAT'S NEW

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 October 2017</td>
<td>New citation required but conclusions have not changed</td>
<td>Results from latest searches do not change conclusions of this review</td>
</tr>
<tr>
<td>26 April 2017</td>
<td>New search has been performed</td>
<td>Update search run 26 April, 2017. Eight records found and assessed by editorial base Cochrane Schizophrenia, no new studies relevant to this review found. The 8 records have been added to Studies awaiting classification of Miscellaneous treatments for antipsychotic-induced tardive dyskinesia (see also Results of the search)</td>
</tr>
</tbody>
</table>

Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia (Review)
Title changed from 'Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia'. Eight new trials added (Chen 1995; Huang 1981; Karniol 1983; Kazamatsuri 1973; Pappa 2010; Rust 1984; Simpson 1988; Soni 1986), analyses and text updated, outcomes' list updated due to patient consultation, 'Summary of findings' table added, conclusions not substantially changed.

### HISTORY

Protocol first published: Issue 1, 1997
Review first published: Issue 1, 2006

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>16 July 2015</td>
<td>Amended</td>
<td>Update search run July 16, 2015. 704 records found and assessed by review authors.</td>
</tr>
<tr>
<td>31 January 2013</td>
<td>Amended</td>
<td>Contact details updated.</td>
</tr>
<tr>
<td>17 October 2012</td>
<td>Amended</td>
<td>Contact details updated.</td>
</tr>
<tr>
<td>18 January 2012</td>
<td>Amended</td>
<td>Contact details updated.</td>
</tr>
<tr>
<td>14 April 2010</td>
<td>Amended</td>
<td>Contact details updated.</td>
</tr>
<tr>
<td>11 November 2009</td>
<td>Amended</td>
<td>Contact details updated.</td>
</tr>
<tr>
<td>26 April 2008</td>
<td>Amended</td>
<td>Converted to new review format.</td>
</tr>
<tr>
<td>5 October 2005</td>
<td>New citation required and conclusions have changed</td>
<td></td>
</tr>
</tbody>
</table>

### CONTRIBUTIONS OF AUTHORS

Hany El-Sayeh - protocol updating, searching, trial selection, data extraction and assimilation (original version).
John Rathbone - selected studies, data extraction, data assimilation (original version).
Karla Soares-Weiser - protocol writing, searching, trial selection, data extraction and assimilation (original version).

### DECLARATIONS OF INTEREST

None known.

KSW is the Deputy Editor-in-Chief for Cochrane and Cochrane Innovations. When the NHIR HTA programme grant relevant to this review update was awarded, KSW was the Managing Director of Enhance Reviews Ltd.

HB worked for Enhance Reviews Ltd. during preparation of this review and was paid for her contribution to this review. Enhance Reviews Ltd. was a private company that performs systematic reviews of literature. HB works for Cochrane Response, an evidence consultancy that takes commissions from healthcare guideline developers and policy makers.
**Sources of Support**

**Internal sources**
- CAPES - Ministry of Education, Brazil.
- Universidade Federal de Sao Paulo, Brazil.
- Academic Unit of Psychiatry, Leeds., UK.
- Enhance Reviews Ltd., UK.

Logistics support for Hanna Bergman for the 2016 update.

**External sources**
- NIHR HTA Project Grant, reference number: 14/27/02, UK.
  - Salary support for Hanna Bergman.
  - Support for patient involvement consultation.
  - Support for traceable data database.

**Differences between protocol and review**

The protocol as published with this review has evolved over time. The revisions of protocol are in line with the development of RevMan and in keeping with Cochrane guidance. We think the revisions have greatly improved and enhanced this review. We do not think, however, that it has materially affected our conduct of the review or interpretation of the results.

In the 2017 review update, the biggest changes to affect the review methods were to:

1. broaden the inclusion criteria, and add the comparison 'Non-antipsychotic catecholaminergic drug vs other drug';
2. change the title from 'Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia' to 'Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia';
3. update list of outcomes following consultation with consumers; and
4. add 'Summary of findings' tables.

Previous methods are reproduced in Appendix 1.

**Index Terms**

**Medical Subject Headings (MeSH)**
- Adrenergic Uptake Inhibitors [therapeutic use]; Anti-Dyskinesia Agents [*therapeutic use]; Antipsychotic Agents [*adverse effects]; Celiprolol [therapeutic use]; Disease Progression; Dopamine Antagonists [therapeutic use]; Dyskinesia, Drug-Induced [*drug therapy]; Haloperidol [therapeutic use]; Methyl dopa [therapeutic use]; Randomized Controlled Trials as Topic; Reserpine [therapeutic use]; Tetrabenazine [therapeutic use]; Tiapamil Hydrochloride [therapeutic use]

**MeSH check words**
- Humans